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Breast cancer is the most common cancer diagnosed in women in the United States. The basal-
like breast cancer subtype represents about 12% of breast cancer and has the worst outcome in 
patients due to lack of effective therapies. Tumor stroma plays an important role in cancer 
progression. Cancer associated fibroblasts (CAFs) are the most abundant stromal cells in breast 
cancer, but their function in cancer progression has not been fully understood. We previously 
identified that the chemokine CCL2 was highly expressed in breast cancer associated fibroblasts. 
CCL2 is known to recruit monocyte/macrophage and promotes cancer progression. We 
previously found that recombinant CCL2 can directly signal to breast cancer cells and promote 
cell survival and invasion in vitro. In this study, we aimed to determine the functional 
importance of CCL2 signaling mediated fibroblast-cancer cell interactions in the breast cancer 
progression. We evaluated the expression of CCL2 and fibroblast marker Fsp1 in breast cancer 
tissue microarray containing 427 samples by immunohistochemistry. Expression of CCL2 and 
Fsp1 were co-upregulated in invasive ductal carcinoma compared to normal breast. High stromal 
CCL2 expression associated with reduced recurrence free survival in the basal-like subtype. 
Further data mining in the breast cancer TCGA and METABRIC datasets revealed that the 
CCL2/CCR2 pair expressed highest in the basal-like subtype. We confirmed high CCL2 
expression from CAFs isolated from primary human and mouse breast cancer samples. CAFs 
with high CCL2 expression significantly promoted xenograft growth when co-grated with human 
basal-like breast cancer MCF10A-CA1D cell line. Reduction of CCL2 expression by CRISPR 
mutation or shRNA knockdown in human or mouse CAFs significantly reduced tumor growth in 
the co-graft model. Fibroblasts condition medium or recombinant CCL2 directly promoted 
CA1D cancer cell growth in vitro. Mutation of the CCL2 receptor CCR2 receptor in CA1D 
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cancer cell significantly reduced cancer cells growth in vitro and in vivo in response to CCL2 
stimulation. The CCL2/CCR2 signaling activated PKC and SRC pathways in cancer cells, and 
contributed to growth promotion. We aimed to test the therapeutic efficacy by blocking CCL2 in 
breast cancer mouse model through continuous delivery of CCL2 neutralizing antibody. Despite 
the steady delivery of the antibody, CCL2 blocking did not significantly affect tumor 
progression. Examination of CCL2 level in blood and tumor sites revealed that CCL2 blocking 
significantly induced higher free CCL2 level, which may contribute to lack of efficacy. In 
summary, our studies have showed that CCL2 derived from cancer associated fibroblasts plays 
an important role in basal-like breast cancer progression. Direct signaling to cancer cells via 
CCR2 is an important mechanism in CCL2 function. Thus, the CCL2/CCR2 signaling may serve 
as potential therapeutic targets in basal-like breast cancer. CCL2 blocking by neutralizing 
antibody can lead to undesired increased CCL2 level, and alternative targeting approaches are 
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 Breast cancer is the most common form of cancer diagnosed in women in U.S., with an 
estimated 252,710 new cases of invasive breast cancer diagnosed in 2017, accounting for 30% of 
total cancer incidences in women (1). Breast cancer is the second leading cause of cancer deaths 
in women, with estimated 40, 610 cases in 2017 (1). It is generally estimated that one in eight 
women will have breast cancer in her life time, and about one-third of those will die of breast 
cancer. 
Pathology 
 Breast cancer rises from epithelial cells lining the milk duct or milk producing lobular 
units (1,2) and is subdivided into ductal carcinoma or lobular carcinoma based on its anatomical 
origin (Figure 1). The normal milk duct consists of two layers of epithelial cells. The luminal 
cells are located inside of the duct and are surrounded by the basal cells on the outside layer. 
Ductal carcinoma is the most common breast cancer, representing about 80% of invasive breast 
cancer, while lobular carcinoma represents about 15% (3). Histologically, ductal carcinoma tends 
to form glandular structures, while lobular carcinoma is less adhesive and often forms individual 
cell file (4). In these studies, we are mostly focused on invasive ductal carcinoma.     
 During breast cancer progression, epithelial cells obtain increased proliferation ability 
due to acquired genomic mutations. When the cancer cells are confined inside the duct, they are 
called ductal carcinoma in situ (DCIS), which is considered benign neoplasm (Figure 1) (1). 
When the cancer cells break the basement membrane and invade into surrounding tissue such as 
fat pad, they are called invasive breast cancer (Figure 1). During disease progression, breast 
cancer will metastasize to draining lymph nodes of breast and to distant organs such as lung, 
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bone and brain. The disease progression and metastasis significantly affect breast cancer patient 
outcome. During 2005-2011, about 61% breast cancers are diagnosed in localized stage, 32% in 
regional stage (metastasis to local breast tissue or lymph node), and 6% in distant metastasis 
stage (metastasis to distant organs). The five-year survival rate is 99% for breast cancer in 






Figure 1.Illustration of breast cancer pathogenesis and progression. 
Figure 1. Illustration of breast 
cancer pathogenesis and 
progression. Image is 
downloaded from 







Stage and Molecular Subtype 
 Breast cancer is often detected by mammogram and palpation of lumps. The disease is 
confirmed by biopsy and clinical pathology. Breast cancer is often diagnosed using classical 
TNM stages, combining information of tumor size and histology (T), local lymph node 
infiltration (N) and distant metastasis (M) (5). The TNM staging system divides breast cancer 
into four stages (stage I to IV), with increased disease burden with increased cancer stage. For 
example, stage I breast cancers are small in size, and contain no or few local lymph node 
infiltration. The tumor size and number/area of lymph node infiltration increases from stage I to 
stage III, while stage IV breast cancer contains distant metastasis (5).   
     Breast cancer is a complex disease and can be further divided into different molecular 
subtypes, which are helpful in prognosis and treatment. Historically, breast cancers are divided 
into five molecular subtypes based on microarray profiling--luminal A, luminal B, Her2, basal-
like and normal like subtypes (6,7). A simplified commercial diagnostic kit has been developed 
to subtype breast cancer by analyzing a list of 50 genes expression (PAM50) (8,9). The most 
convenient method used in the clinic is analyzing expression of three molecular markers: 
estrogen receptor (ER), progesterone receptor (PR) and Her2 overexpression. ER and PR are 
analyzed by immunohistochemistry, and Her2 is analyzed by both immunohistochemistry and 
DNA fluorescent in situ hybridization. Cell proliferation status (characterized by Ki67 
expression) is also used in subtyping. In this method (10), luminal A (70%) is defined by 
expression either ER+ or PR+, and Her2-, and low in Ki67 expressing; luminal B subtype (10%) 
is defined by expression either ER+ or PR+, and high Ki67 expressing; Her2 subtype (15%) is 
defined by Her2+; triple negative subtype (12%) is defined by ER-, PR- and Her2-. 
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     The term basal-like breast cancer is derived from expression profiling analysis 
(microarray or PAM50). Basal-like breast cancer is often characterized by expressing of basal 
cytokeratin (CK5/6, CK14), similar to the basal epithelial cells (6). Luminal breast cancers 
(luminal A and luminal B) express markers similar to luminal epithelial cells, such as cytokeratin 
19 (6). The triple negative breast cancer is characterized by lacking expression of ER, PR and 
Her2. About 71% triple negative breast cancers are basal-like breast cancer by microarray 
profiling. Similarly, about 77% molecular basal-like breast cancers are triple negative (11,12). In 
this thesis, basal-like breast cancer and triple negative breast cancers are used exchangeable 
unless specified. 
Prognosis and Treatment 
 The prognosis and treatment of breast cancer are critically dependent on the cancer stage 
and molecular subtype (1). When breast cancer is diagnosed as localized disease (Stage I to III), 
surgical removal of cancer is often performed. When only partial breast containing tumor is 
removed, it is called lumpectomy; when the whole breast is removed, it is called mastectomy. 
Surgery is often followed by radiation, chemotherapy or targeted therapy. In metastatic breast 
cancer (Stage IV), systematic treatments, such as chemotherapy or targeted therapy are often 
used. ER+ breast cancer can be treated with hormone targeted therapy, such as tamoxifen to 
block ER function. In postmenopausal women with ER+ breast cancer, aromatase inhibitors are 
used as a targeted therapy to block synthesis of estrogen ligand by aromatase. In Her2 positive 
breast cancer, Her2 targeted therapies are used, such as Her2 blocking antibody (Herceptin) or 
chemical inhibitors (Lapatinib).     
 Luminal and Her2+ breast cancer have relative good survival outcome due to available 
targeted therapy. In contrast, the triple negative breast cancer does not respond to those targeted 
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therapies due to loss of expression of ER and Her2, and has the worst patient outcome (7,13). For 
example, in one study on correlation of clinical outcome with molecular subtype defined by  
PAM50, the five-year survival rate for basal-like subtype is about 87%, compared to 99% for 
luminal A and 95% for luminal B or Her2 subtypes (8). Thus, studying the molecular mechanism 
of basal-like breast cancer progression is critical in identifying potential therapeutic targets.  
Cancer associated fibroblasts  
 The stromal environment has emerged as a critical factor in tumor progression (14). 
Tumor stroma consists of extracellular matrix and stromal cells. Cancer associated fibroblasts 
(CAFs) are the most abundant cell types in tumor microenvironment. CAFs are often regarded as 
activated fibroblasts, as they share common features of activated fibroblasts in inflammatory 
condition, such as increased proliferation, secretion of soluble factors and extracellular matrix 
remodeling activity (15). CAFs are a heterogeneous cell population, and they can originate from 
bone marrow cells, tissue residual fibroblasts and epithelial to mesenchymal transition of tumor 
cells (16). A number of markers are commonly used to label CAFs, including fibroblast specific 
protein 1 (Fsp1), fibroblast activation protein (FAP), a-smooth muscle actin (SMA), podoplanin, 
PGDFRβ (15). However, all of those markers are not fibroblast exclusive, and each of them only 
labels a subpopulation of fibroblasts (17).  
 Accumulation of CAFs has been reported in multiple cancer types, such as breast cancer, 
pancreatic cancer, and lung cancer (15). Fibroblasts accumulation is generally associated with 
unfavorable outcome in cancer patients (15). However, fibroblasts labelled with different 
molecular markers are associated with different clinical outcome. For example, accumulation of 
fibroblasts expressing markers of a-SMA (18), PDGFRβ (19) or podoplanin (20) has been 
reported to associate with unfavorable outcome in breast cancer. However, accumulation of 
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fibroblasts expressing FAP marker has been reported to associate with good outcome in breast 
cancer (21). Those studies indicate different lineages of fibroblasts may function differently in 
cancer.  
 The function of fibroblasts in cancer progression is often studied by using mouse genetic 
models and co-culture and co-transplantation studies (15). In mouse genetic models, genetic 
modulation of factors in fibroblasts provides physiological relevant insights. For example, 
conditional knockout of TGFβII receptor in Fsp1+ fibroblast lineage by a Cre recombinase 
expressed under Fsp1 promoter, led to spontaneous tumor formation in prostate and forestomach, 
indicating a critical role of fibroblasts in controlling tumor formation (22). In another study, 
genetic ablation of FAP positive fibroblasts in pancreatic cancer model led to a better response to 
immunotherapy (23). However, other studies using genetic depletion of a-SMA expressing CAFs 
in mouse pancreatic cancer model have resulted in accelerated disease progression, indicating an 
unexpected tumor suppression role (24,25). However, the genetic models are limited by the 
lacking of fibroblast specific Cre recombinase expression, as most of the fibroblasts Cre mouse 
lines mentioned above also expressed in other cell lineages. A complimentary method is using 
CAFs isolated from tumor samples and studying their function using fibroblast-cancer cell co-
culture and co-transplantation models. Those studies also provided important insights in the roles 
of CAFs in cancer growth and metastasis, such as promoting angiogenesis and cancer cell 
invasion (15). The fibroblasts heterogenicity and multiple functions indicate a complex role in 
cancer progression. A better understanding of CAFs function is needed in order to develop 
fibroblasts targeted therapy in cancer.   
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Chemokine CCL2 signaling and functions 
 Chemokines are small soluble proteins (8-10 kDa) that regulate homing and recruitment 
of immune cells through formation of molecular gradients (26). Chemokines are highly 
conserved between mice and humans. They play important roles in regulating immune cell 
trafficking and endothelial sprouting during embryonic development, wound healing and 
infections (26). Currently, more than 47 ligands and 23 receptors have been identified and 
classified into the multiple categories, depending on the spacing of the cysteine motif present at 
the N terminus of the chemokine ligand (26).  
 CCL2 belongs to the C-C class of chemokines, which contain two pairs of conserved 
cysteine residues. Also known as Monocyte Chemoattractant Protein 1 (MCP-1), CCL2 is a 
potent chemokine in inducing monocyte migration (27). CCL2 can bind to multiple receptors 
including CCR2, CCR4 and CCR5 in vitro, but it has the highest binding affinity with CCR2 
(27,28). In mouse model, knockout of CCL2 and CCR2 show similarly phenotype in defects in 
monocyte migration (29,30). Besides CCL2, CCL7 also binds with CCR2 receptor and functions 
in the process of monocyte recruitment. CCL7 knockout mouse also shows defect in monocyte 
migration (31).  Those studies suggest that CCL2 and CCL7 function non-redundantly in 
recruiting monocyte in mouse functioning through CCR2 receptor.  
 Overexpression of CCL2 has been implicated in inflammatory diseases, including 
rheumatoid arthritis, macular degeneration, diabetes and atherosclerosis (27,32). CCL2 is 
overexpressed in the epithelium and stroma of numerous cancer types, including gliomas, 
prostate cancers, ovarian cancers and breast cancers, and expression correlates with recruitment 
of macrophages (32-34). CCL2 expression correlates with tumor grade and unfavorable patient 
prognosis from studies of tumor biopsies and blood serum levels of cancer patients (32).   
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 Expression of CCL2 in cancer has been observed in multiple cell types, including 
epithelial cancer cells, fibroblasts, endothelial cells, and macrophages (32). However, the 
contribution of each individual cellular source of CCL2 is undefined. A few studies indicate an 
unequal contribution of different sources. In one clinical association study, the authors reported 
that stromal CCL2 significantly associated unfavorable outcome in breast cancer, while epithelial 
CCL2 did not (35).  In a breast cancer xenograft mouse model, CCL2 from human cancer cells 
or mouse stromal cells both functioned in promoting lung metastasis, revealed from CCL2 
blockade studies using human or mouse specific CCL2 neutralizing antibody (36). Grafting 
breast cancer cells into CCL2 mutant mouse hosts also resulted in reduced primary tumor growth 
and metastasis, compared to wildtype control (37). All those studies indicate that the stromal 
cells are important cellular sources of CCL2. Early studies in our laboratory showed that CAFs 
with TGFβII knockout produced a significantly higher level of chemokine CCL2, and promoted 
mammary tumor cells metastasis (38). In following up studies with human breast cancer 
samples, increased expression of CCL2 was observed in cancer cells and stromal cells (39). 
Those studies indicate that cancer associated fibroblasts may serve as an important cellular 
source of chemokine CCL2 in breast cancer progression.  
 The majority of CCL2 function in breast cancer is focused on immune cell recruitments. 
In lung metastasis model, CCL2 has been shown to induce inflammatory monocyte migration 
and   promote vascular permeability through VEGF expression. This promotes cancer cells 
extravasation and increases lung metastasis (36). Inhibition of CCL2 by blocking antibody 
reduces lung metastasis (36). CCL2 expression in primary breast cancer is also associated with 
macrophage infiltration and angiogenesis (37,40). CCL2 can also recruit immunosuppressive 
myeloid derived suppressor cells, and inhibits anti-tumor immunity (41).   
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 The expression of receptor CCR2 has been reported in multiple cancer cells (39,42-44), 
indicating a potential role for CCL2 signaling to cancer cells. A few in vitro studies have shown 
that CCL2 can signal directly to cancer cells. An earlier study in our laboratory reported that 
recombinant CCL2 promoted breast cancer cells invasion and survival in vitro (39). CCL2 has 
been reported to promote cancer stem cells formation in Her2+ breast cancer cells in vitro (45). 
However, the functional importance of CCL2 signaling to cancer cells has not been directly 
tested in vivo. Most in vivo studies are performed with CCL2 knockdown or blocking (36,40,45), 
thus those results cannot distinguish the CCL2 effects on stromal immune cells or cancer cells.  
Hypothesis and outline of contents  
 Those preliminary studies led us to hypothesize that CCL2 derived from cancer 
associated fibroblasts promotes breast cancer progression by signaling to cancer cells via 
CCR2 (Figure 2). In the following three chapters, we have addressed this hypothesis through 
both human cancer samples analysis and mouse models studies. We briefly summarize the 
contents of the following four chapters as below:  
 
Chapter II: Expression of CCL2 and fibroblast marker Fsp1 in breast cancer 
Figure 2. Overall hypothesis and model. 
Figure 2. Overall hypothesis and model. 
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 In this chapter, we have evaluated the prognostic significance of CCL2 protein 
expression in breast cancer subtypes, in relation to its expression in the epithelium or stroma, or 
in relation to Fibroblast Specific Protein 1 (Fsp1), a mesenchymal marker.  
Immunohistochemistry analysis of tissue microarrays revealed that CCL2 significantly correlated 
with Fsp1 expression in the stroma and tumor epithelium of invasive ductal carcinoma. In the 
overall breast cancer cohort (n=427), CCL2 and Fsp1 expression in whole tissues, stroma and 
epithelium were inversely associated with cancer stage and tumor size. When factoring in 
molecular subtype, stromal CCL2 was observed to be most highly expressed in Basal-like breast 
cancers. By Cox Regression Modeling, stromal CCL2, but not stromal Fsp1 expression was 
significantly associated with decreased recurrence free survival. Furthermore, stromal CCL2 
(HR= 7.51 p=0.007) was associated with a greater hazard than cancer stage (HR=2.54, p=0.045) 
and tumor grade (HR=0.41, p=.0871). These studies indicate that stromal CCL2 is associated 
with decreased recurrence free survival in patients with basal-like breast cancer, with important 
implications on the use of stromal markers for predicting patient prognosis. 
Chapter III: Function of the CCL2/CCR2 signaling in fibroblasts and breast cancer cells 
interaction 
 In this chapter, we have studied the function of chemokine CCL2 derived from cancer 
associated fibroblasts, and the role of direct CCL2/CCR2 signaling in basal-like breast cancer 
cells. Our studies indicate that fibroblast mediated CCL2/CCR2 signaling promotes the growth 
of basal-like breast cancers independent of these stromal responses. Knockdown of CCL2 in 
fibroblasts or knockout of CCR2 in breast cancer cells abrogates fibroblast mediated growth of 
MCF10CA1d breast cancer cells, independently of macrophage recruitment or tumor 
angiogenesis. In vitro, MCF10CA1d cells grow less dense, when treated with conditioned 
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medium from stromal cells deficient in CCL2.  SRC or PKC inhibitors block CCL2/CCR2 
mediated growth of breast cancer cells. Datamining analysis indicates that CCL2 and CCR2 are 
most highly expressed in basal-like breast cancers. These studies demonstrate a novel 
mechanism regulating basal-like breast cancer progression involving CCL2/CCR2 signaling in 
cancer cells. Thus, the CCL2/CCR2 signaling may serve as potential therapeutic targets in basal-
like breast cancer. 
Chapter IV: Therapeutic targeting the CCL2 signaling in breast cancer model 
 In this chapter, we have investigated the effects of continuous delivery of human CCL2 
neutralizing antibodies on breast cancer progression. Nude mice bearing MCF10CA1d breast 
tumor xenografts were implanted with osmotic pumps containing control IgG or anti-CCL2, and 
analyzed for CCL2 levels, and tumor progression over 4 weeks.  Despite inhibiting CCL2-
induced migration in vitro, CCL2 neutralizing antibodies did not significantly affect tumor 
growth, invasion, macrophage recruitment or tumor angiogenesis. CCL2 antibodies did not affect 
murine CCL2 levels but significantly increased human CCL2 levels in circulating blood and 
tumor interstitial fluid. CCL2 neutralizing antibodies reduced CCL2 levels in cultured cells 
short-term at high concentrations. ELISA analysis of CCL2 in cultured fibroblasts and breast 
cancer cells revealed that the neutralizing antibodies sequestered CCL2 in the media. CCL2 
levels were restored once the antibodies were removed. These studies reveal limitations in CCL2 
neutralizing antibodies as a therapeutic agent, with important implications for translating CCL2 
targeting to the clinic. 
Chapter V: Conclusion and Discussion 
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 In this chapter, we have highlighted the overall importance of our founding and the 
potential applications. In addition, we will also discuss the limitations of our studies and 
additional questions not addressed in our studies. We also propose follow up studies and future 
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Contents in this chapter have been published in:  
Yao, M., E. Yu, V. Staggs, F. Fan and N. Cheng (2016). "Elevated expression of chemokine C-C 







     Treatment of breast cancer is complicated by the presence of different molecular 
subtypes. These subtypes include:  Luminal A, Luminal B, Her2 overexpressing (Her2+) and 
Basal-like breast cancers. Histologically, these subtypes are classified by the status of estrogen 
receptor (ER), progesterone receptor (PR), Her2, and cell proliferative index (46-49).  
Conventional prognostic indicators such as grade and stage do not accurately predict patient 
prognosis for all of the different molecular subtypes (50,51), indicating the need to identify 
prognostic factors unique to each subtype.  
     Recent studies demonstrate that the stroma of invasive breast cancers express high levels 
of Chemokine C-C Ligand 2 (CCL2). Previous studies have primarily examined CCL2 
expression for its association with macrophages in breast cancer and patient prognosis and have 
reported different results (35,52,53).  In previous studies, we demonstrated an important 
biological role for CCL2 overexpression in breast cancer cells and in fibroblasts in regulating 
tumor progression (38,54). These studies suggest that multiple factors could affect the prognostic 
relevance of CCL2 expression in breast cancer. 
     In these studies, we employed several novel approaches to evaluate the prognostic 
significance of CCL2 expression in breast cancer. Here, we employed a software based approach 
to evaluate the prognostic significance of CCL2 protein expression in breast cancer subtypes, in 
relation to its expression in the epithelium or stroma, or in relation to Fsp1, a mesenchymal 
marker.   Immunohistochemistry analysis of tissue microarrays revealed that CCL2 significantly 
correlated with Fsp1 expression in the stroma and tumor epithelium of invasive ductal 
carcinoma. In the overall breast cancer cohort, CCL2 and Fsp1 expression in whole tissues, 
stroma and epithelium were inversely associated with cancer stage and tumor size. When 
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factoring in molecular subtype, stromal CCL2 was observed to be most highly expressed in 
Basal-like breast cancers. By Cox Regression Modeling, stromal CCL2, but not stromal Fsp1 
expression was significantly associated with decreased recurrence free survival. Furthermore, 
stromal CCL2 (HR= 7.51 p=0.007) was associated with a greater hazard than cancer stage 
(HR=2.54, p=0.045) and tumor grade (HR=0.41, p=.0871). Our studies have important 
implications on the use of stromal markers for predicting prognosis of patients with Basal-like 
breast cancer. 
Materials and methods  
Patient samples 
 A total of 12 prognostic tissue microarray slides (6 slides in duplicate) were obtained 
from the National Cancer Institute Cancer Diagnostics Program. Each array slide contained 90-
100 breast cancer core samples and 5 normal breast tissue cores, 3 fibroadenoma cores, and 20 
control core samples comprised of prostate, colon and salivary gland and endometrium tissues.  
De-identified carcinoma or matching normal adjacent tissue samples were collected from 
patients who were diagnosed with breast cancer between 1985 and 1997, prior to adjuvant 
therapy.  The majority of those patients (85%) received adjuvant radiation, chemo- or hormone 
therapy, or a combination of therapies. The mean follow-up time was 104 months, with a 
maximal follow-up time of 276 months. Pathology reports included information on: clinical 
diagnosis, treatment regimen, age, stage, tumor size, grade, lymph node status, mitotic score and 
intensity of biomarker staining for ER, PR and Her2. Patient outcome included information on: 
metastasis, recurrence, survival and follow-up time.  
17 
 
     5 de-identified normal breast tissue samples and 32 core samples of stage I-IV breast 
ductal carcinoma were obtained in duplicate from the Biospecimen Core Repository at the 
University of Kansas Medical Center. This cohort included pathology information on:  age, 
stage, grade, tumor size, Ki67 expression and intensity of biomarker staining for ER, PR and 
Her2.  Outcome information included: status on survival, recurrence, and number of recurrences. 
Treatment information was not available.  
     The clinical pathologic features of both datasets are summarized (Table 1). When the 
patient datasets were combined, the mean age of patients was 59 years, with a mean follow-up 
time of 8.7 years.  
Immunohistochemistry 
 Tissue microarray slides were de-paraffined and rehydrated through a series of xylenes 
and 100%, 95%, 70% and 50% ethanol. For CCL2 immunostaining, slides underwent antigen 
retrieval through low pressure cooking in 2M urea for 2 min. Peroxidases were quenched for 30 
minutes in PBS containing 3% H202 and 10% Methanol, and blocked in PBS containing 3% 
Fetal bovine serum for 1 hour. Slides were incubated with goat anti-human CCL2 antibody at a 
1:100 dilution (cat no. sc-1304, Santa Cruz Biotechnology, Santa Cruz, CA) overnight in 
blocking buffer, and with biotinylated horse anti-goat antibody(Vector Laboratory, BH-9500, 
1:1000) in room temperature for two hours. For Fsp1 immunostaining, slides underwent antigen 
retrieval through low pressure cooking in 10 mM sodium citrate pH 6.8 for 2 minutes. After 
peroxidase quenching and blocking, slides were incubated with rabbit anti-Fsp1 at a 1:3 dilution 
(cat no. ab-27427, Abcam, Cambridge, MA) in blocking buffer overnight, and then with 
peroxidase conjugated goat anti-rabbit antibody at a 1:1000(cat no. 611-1302, Rockland 
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Immunochemicals, Pottstown, PA) for 2 hours at room temperature.  Expression of CCL2 and 
Fsp1 proteins were detected with streptavidin-peroxidase (cat no. PK-6100, Vector Laboratories, 
Burlingame, CA) and 3,3'-diaminobenzidine (DAB) substrate. Slides were counterstained with 
Harris’s hematoxylin, dehydrated and mounted with Cytoseal (cat no. 8312-4, Thermo Fisher 
Scientific, Lenexa, KS). Images were acquired using a Motic AE31 inverted microscope with 
camera and Q capture software. 
     For immunofluorescence staining, CCL2 expression was detected through incubation 
with secondary donkey anti-goat conjugated to Alexa Flour-488 at a 1:1000 dilution (cat no. 
R37118, Thermo Fisher Scientific). To detect Fsp1, slides were incubated with secondary rabbit 
biotinylated antibodies, conjugated to streptavidin- Alexa Flour-568 (cat no. s-11226, Thermo  
Fisher Scientific). Slides were counterstained with DAPI and mounted in PBS containing 50% 
glycerol.    
Image quantification 
 Images of immunohistochemistry staining were acquired at 10x magnification using a 
Motic AE31 inverted microscope with Infinity 2-1x color digital camera.  Software analysis of 
biomarker expression in breast tissues was performed using methods previously described (55).  
Images were first imported into Adobe Photoshop. Color and exposure of images were 
normalized using auto-contrast. Tumor epithelium was distinguished from the stroma by 
differences in nuclear and cellular morphology, and tissue architecture.  To select for specific 
tissues, the lasso tool was to select and crop out stroma or epithelium. The stromal tissues were 
labeled as “total stromal area” while the epithelial tissues were labeled as “total epithelial area.” 
DAB staining, identified as brown, was selected using the Magic Wand tool in the Color Range 
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Window, with a specificity range of 66. Selected pixels were copied to a new window and saved 
as a separate file. Images were opened in Image J software (NIH) and converted to greyscale. 
Background pixels resulting from luminosity of bright field images were removed by threshold 
adjustment. Images were the subject to particle analysis. DAB staining and total areas were 
expressed as particle area values of arbitrary units. Positive DAB values were normalized total 
stromal or epithelial values. 
Statistical analysis   
 Sample populations did not fit a Gaussian distribution, and were observed to be uneven. 
The uneven characteristic was due to two factors. Information on prognostic factors was not 
provided for all patients within the two cohorts.  In addition, some tissue samples on the tissue 
microarray did not adhere to the slide during staining.  As such, protein expression values and 
their relationships to clinical data were analyzed using non-parametric methods. Statistical 
analyses were performed using Graphpad Software and SAS. 
     The samples from the two cohorts were combined. Comparison of two groups with 
discrete variables was performed using Wilcoxon Two-Sample Test. Tests for association 
between CCL2 and Fsp1 were performed using Spearman Correlation Analysis.   Analysis of 
three or more groups was performed using Kruskal-Wallis Test with Dunn’s post-hoc 
comparison between groups. Cox regression model for non-proportional hazards was used for 
univariate and multivariate analysis. Expression levels of CCL2 and Fsp1 in the Cox regression 
model were transformed by multiplying values by 10 so that values were greater than 1. 
Statistical significance was determined by p <0.05.  Factors approaching significance were 
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further selected for multi-variate analysis.   *p<0.05, **p<0.01, ***p<0.001, unless otherwise 
specified. 
Ethics statements 
 The tissues collected for these studies were de-identified and classified as “Exempted” 
according to regulations set forth by the Human Research Protection Program (ethics committee) 
at the University of Kansas Medical Center (#080193). Written informed consent for tissue 
collection was obtained by the Biospecimen core repository. Tissue samples were de-identified 
prior to distribution to the investigators. Existing medical records were used in compliance with 
the regulations of the University of Kansas Medical Center and National Cancer Institute. These 
regulations are aligned with the World Medical Association Declaration of Helsinki. 
Results 
CCL2 and Fsp1 are co-expressed in breast cancer 
 To characterize the expression patterns of CCL2 and Fsp1 in breast cancer, we performed 
immunohistochemistry staining on breast cancer tissue microarray obtained from the National 
Cancer Diagnostics Program and the University of Kansas Medical Center Biospecimen Core 
Repository. To circumvent possible bias caused by visual scoring of tissues, we utilized an 
Image J software based approach to quantify protein expression (55). Expression patterns were 
compared among normal breast tissues, fibroadenoma tissues, which are non-malignant breast 
lesions, and invasive breast carcinoma tissues. Of the invasive breast cancer cases, 91% were 
comprised of invasive ductal carcinoma and 9% were diagnosed as invasive lobular carcinoma.  
Expression CCL2 and Fsp1 proteins were detected in the stroma and epithelium of normal breast 
tissues, fibroadenoma, invasive lobular carcinoma and invasive ductal carcinoma (Figure 3A). 
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When quantified in whole tissues, CCL2 and Fsp1 were most highly expressed in invasive ductal 
carcinoma tissues, compared to the other tissue types (Figures 3B-C).  By Spearman correlation 
analysis, CCL2 was significantly associated with Fsp1 expression in whole tissues, in the stroma 
and in the epithelium of invasive ductal carcinoma (Figures 4A-C). By co-immunofluorescence 
staining of invasive ductal carcinoma samples, CCL2 was found to significantly overlap with 
Fsp1 expression in the stroma and tumor epithelium (Figure 4D). These data demonstrate 




Table 1. Clinical-pathological features of tumor samples in the NCI and KUMC TMAs 
combined. 
 
Factors Sample size (% of total) 
Age (years)   
    <50 130 (30%) 
    >=50 297 (70%) 
Histology type   
    Ductal  388 (91%) 
    Lobular 38 (9%) 
    Unknown 1 (0.2%) 
T stage   
    T1 90 (21%) 
    T2 196 (46%) 
    T3 88 (21%) 
    T4 42 (10%) 
    Unknown 11 (3%) 
N stage   
    N0 92 (22%) 
    N1 266 (63%) 
    N2 54 (13%) 
    N3 3 (1%) 
    Unknown 12 (3%) 
Grade    
    I 61 (14%) 
    II 197 (46%) 
    III 167 (39%) 
    Unknown 2 (0.5%) 
ER status   
    Negative 145 (34%) 
    Positive 271 (63%) 
    Unknown 11 (3%) 
PR status   
    Negative 168 (39%) 
    Positive 247 (58%) 
    Unknown 12 (3%) 
Her2 status   
    Normal 339 (79%) 
    Overexpression 76 (18%) 
    Unknown 12 (3%) 




    
Figure 3. Expression of CCL2 and Fsp1 proteins in breast tissues. TMAs containing 
samples of normal breast (n=20), fibroadenoma (Fibro, n=9), invasive lobular carcinoma 
(ILC, n=38) and invasive ductal carcinoma (IDC, n=388) breast cancer were immunostained 
for CCL2 and Fsp1. Expression levels were quantified by Image J; arbitrary units are shown. 
(A) Representative images of CCL2 and Fsp1 expression. Scale bar= 100 microns. 
Comparison of CCL2 (B) and Fsp1 (C) expression among different groups using Kruskal-
Wallis Test with Dunn’s post-hoc comparison. Statistical significance was determined by 
*p<0.05; **p<0.01, ***p<0.001.  




Figure 4. CCL2 is significantly associated with Fsp1 expression in IDC.  Associations 
between CCL2 and Fsp1 expression in whole tissue (total) (A), stroma (B) or epithelium (C) in 
IDC were analyzed by Spearman Correlation analysis. Statistical significance was determined by 
p<0.05. Correlation co-efficient (r) and 95% confidence interval (95% CI) are shown. (D). Co-
immunofluorescence staining for CCL2 and Fsp1 in IDC. Magnified inset shows overlapping 
staining. Secondary antibody staining only is shown as negative control. Scale bar= 400 microns. 
Figure 4. CCL2 is significantly associated with Fsp1 expression in IDC 
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CCL2 and Fsp1 expression do not significantly associate with patient outcome in the 
overall cohort                                                                                                                               
 We then analyzed for associations between CCL2 or Fsp1 with commonly used 
prognostic factors in IDC.  Whole tissue (total) expression of CCL2 and Fsp1 inversely 
correlated with overall stage and T stage (Figures 5A-B). Total Fsp1 but not total CCL2 
expression inversely correlated with N stage (Figure 5C). Total expression of CCL2 and Fsp1 
was not associated with tumor grade, ER, PR or Her2 status (Table 2). Similarly, stromal and 
epithelial expression of CCL2 and Fsp1 negatively correlated with overall stage and T stage 
(Tables 3 and 4). In contrast to total CCL2 expression, stromal CCL2 expression negatively 
correlated with Her2 overexpression. In contrast to total Fsp1 expression, epithelial Fsp1 
positively correlated with ER and PR status (Tables 3 and 4). In summary, these data indicate 
that CCL2 and Fsp1 inversely associate with stage and tumor size, and that associations with ER, 
PR and Her2 status are dependent on tissue specific patterns of expression.  We next determined 
whether CCL2 and Fsp1 expression were associated with patient outcome. To adjust for multiple 
variables that might affect the association of CCL2 and Fsp1 expression with patient outcome, 
univariate Cox regression analysis was first performed for overall survival (Table 5).  Tumor 
size, lymph node status and histologic grade were associated with decreased overall survival, 
with Hazard Ratios of 1.58 or more and p-values of less than 0.01. Among adjuvant therapies as 
possible factors, chemotherapy was associated with decreased overall survival (HR=1.42, 
p=0.046). Radiation therapy and hormone treatment were not significantly associated with 
overall survival. Among expression of biomarkers, the absence of ER and PR significantly 
associated with decreased overall survival, with Hazard Ratios of 1.84 or more, and p-values less 




Figure 5. CCL2 and Fsp1 proteins are associated with overall stage and T stage in 
IDC. Total CCL2 and Fsp1 expression were analyzed for associations with overall stage 
(A), T stage (B) and N stage (C). Statistical analysis was performed using Mann-
Whitney’ test (overall stage) or Kruskal-Wallis Test with Dunn’s post-hoc comparison (T 
stage and N stage). Statistical significance was determined by *p<0.05; **p<0.05, 
***p<0.001 and n.s. = not significant. 
Figure 5. CCL2 and Fsp1 proteins are associated with overall stage and T stage in IDC 
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Table 2. Associations of total CCL2 and Fsp1 expression with clinico-pathological factors. 
Univariate analyses were performed using Mann Whitney Test for two groups or Kruskal-Wallis 
Test with Dunn’s post-hoc comparisons for three or more groups. Statistical significance was 
determined by p<0.05.   
Factors 










Stage       
    II 173 0.036 
<0.0001 
  213 0.347 
<0.0001 
    III 130 0.020   139 0.252 
T stage               
    T1 68 0.038 
0.002 
  76 0.308 
0.001 
    T2 138 0.033   169 0.341 
    T3 65 0.020   73 0.253 
    T4 36 0.015   38 0.278 
N stage               
    N0 59 0.031 
0.613 
  78 0.359 
0.001     N1 201 0.029   226 0.308 
    N2 43 0.028   48 0.245 
Grade               
    I 41 0.020 
0.679 
  47 0.319 
0.470     II 135 0.028   159 0.297 
    III 139 0.031   158 0.316 
ER status               
    Negative 122 0.028 
0.565   130 0.311 0.907 
   Positive 188 0.029   226 0.309 
PR status               
    Negative 133 0.027 
0.214 
  148 0.306 
0.627 
    Positive 177 0.030 
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  207 0.314 
Her2 status               
    Normal 248 0.030 
0.072 
  284 0.315 
0.302 
Overexpression 62 0.025   71 0.294 




Table 3. Associations of stromal CCL2 and Fsp1 expression with clinico-pathological 
factors. Univariate analyses were performed using Mann Whitney Test for two groups or 
Kruskal-Wallis Test with Dunn’s post-hoc comparisons for three or more groups. Statistical 







value  p-value   N 
Mean expression 
value  p-value 
Stage       
    II 152 0.016 
<0.0001 
  201 0.320 
<0.0001 
    III 121 0.007   131 0.225 
T stage               
    T1 62 0.015 
<0.0001  
  74 0.284 
0.001 
    T2 121 0.015   158 0.312 
    T3 59 0.006   70 0.223 
    T4 35 0.005   38 0.278 
N stage               
    N0 51 0.014 
0.407 
  71 0.336 
<0.001     N1 182 0.012   217 0.281 
    N2 40 0.011   44 0.215 
Grade               
    I 40 0.011 
0.517 
  47 0.274 
0.254     II 125 0.012   154 0.270 
    III 120 0.012   143 0.296 
ER status     
  
  
    
  
    Negative 106 0.012 
0.203 
  118 0.295 
0.319 
    Positive 174 0.012   218 0.276 
PR status               
    Negative 118 0.012 
0.117   136 0.281 0.689 
    Positive 162 0.012   199 0.285 
Her2 status               
    Normal 225 0.013 
0.039 
  270 0.289 
0.325 
    
Overexpression 55 0.009   65 0.264 
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Table 3. Associations of stromal CCL2 and Fsp1 expression with clinico-pathological factors 
Table 4. Associations of epithelial CCL2 and Fsp1 expression with clinic-pathological 
factors. Univariate analyses were performed using Mann Whitney Test for two groups or 
Kruskal-Wallis Test with Dunn’s post-hoc comparisons for three or more groups Statistical 














Stage       
    II 157 0.062 
<0.0001 
  180 0.421 
<0.0001 
    III 123 0.035   120 0.319 
T stage               
    T1 61 0.069 
0.000 
  71 0.394 
0.002 
    T2 126 0.054   140 0.411 
    T3 62 0.036   60 0.322 
    T4 35 0.027   33 0.324 
N stage               
    N0 57 0.052 
0.749 
  68 0.398 
0.051     N1 184 0.050   187 0.389 
    N2 39 0.050   45 0.321 
Grade               
    I 35 0.043 
0.459 
  41 0.447 
0.049     II 125 0.054   135 0.373 
    III 132 0.046   136 0.367 
ER status               
    Negative 112 0.043 
0.106 
  110 0.351 
0.034 
    Positive 176 0.053   196 0.399 
PR status               
    Negative 120 0.043 
0.057 
  127 0.355 
0.043 
    Positive 168 0.054   178 0.401 
Her2 status               
    Normal 234 0.051 
0.258 
  246 0.386 
0.530   
Overexpression 54 0.043   59 0.365 




Table 5. Univariate Cox Regression model on the association of CCL2 and Fsp1 expression 
with outcome of patients with IDC. The Hazard Ratio (HR) was calculated from the Cox 
Proportional Hazard Regression Model. 95% confidence interval (CI) of the calculated HR is 




Recurrence free survival 
HR 95% CI p-value 
 
HR 95% CI p-value 
T stage 
   
 
    
 
    T1 1.00 0.99 1.02 0.644 
 
1.00 0.99 1.01 0.965 
    T2 1.59 0.95 2.67  
 
1.62 1.01 2.58  
    T3 3.64 2.12 6.23 
 
2.39 1.40 4.07 
    T4 1.97 0.97 3.98 
 
2.30 1.20 4.41 
N stage 
   
  
    
  
    N0 1.00 
  0.002  
1.00 
  <0.001     N1 1.58 0.98 2.54 
 
1.38 0.89 2.14 
    N2 2.89 1.61 5.21 
 
2.99 1.72 5.19 
Grade 
   
  
    
  
    I 1.00 
  0.002  
1.00 
  0.009     II 3.79 1.64 8.75 
 
2.24 1.18 4.25 
    III 4.62 2.00 10.65 
 
2.69 1.42 5.09 
Chemotherapy 
   
 
    
 
    No 1.00 
  0.046  
1.00 
  0.037     Yes 1.42 1.01 2.02 
 
1.43 1.02 2.00 
Radiation therapy 
   
 
    
 
    No 1.00 
  0.513  
1.00 
  0.114     Yes 1.13 0.79 1.61 
 
1.32 0.94 1.85 
Hormone therapy 
   
 
    
 
    No 1.00 
  0.635  
1.00 
  0.563     Yes 0.92 0.65 1.30 
 
1.10 0.79 1.53 
ER status 
   
 
    
 
    Positive 1.00 





    Negative 1.92 1.37 2.70 
 
1.75 1.26 2.44 
PR status 
   
 




    Positive 1.00 





    Negative 1.84 1.32 2.58 
 
1.70 1.22 2.37 
Her2 status 
   
  
    
  
    Normal 1.00 
  0.127  
1.00 
  0.134 
    Overexpression 1.37 0.91 2.06 
 
1.35 0.91 2.01 
CCL2 total 0.01 0.00 2.83 0.111 
 
0.01 0.00 2.25 0.096 
CCL2 stromal 1.01 0.36 2.85 0.984 
 
1.37 0.52 3.59 0.522 
CCL2 epithelial 0.03 0.00 1.59 0.085 
 
0.03 0.00 1.19 0.062 
Fsp1 total 0.55 0.19 1.58 0.266 
 
0.60 0.22 1.68 0.334 
Fsp1 stromal 0.51 0.17 1.49 0.218 
 
0.53 0.19 1.51 0.235 
Fsp1 epithelial 0.55 0.19 1.59 0.273 
 
0.78 0.29 2.11 0.620 
Table 5. Univariate Cox Regression model on the association of CCL2 and Fsp1 expression with outcome of 





Expression of CCL2 and Fsp1 proteins in whole tissue, stroma and epithelium were not 
associated with overall survival.  We next examined for associations with recurrence free 
survival (Table 5). Tumor size, lymph node status and histologic grade were associated with 
decreased recurrence free survival with Hazard Ratios of 1.38 or more and p-values less than 
0.01.  Chemotherapy, but not anti-hormonal or radiation therapy, was associated with decreased 
relapse-free survival with Hazard Ratio of 1.43 and p=0.037. ER and PR, but not Her2 were 
associated with decreased recurrence free survival with Hazard Ratios of 1.70 or more, and p-
values of less than 0.01. Expression of CCL2 and Fsp1 proteins in whole tissue, stroma and 
epithelium were not associated with recurrence free survival. In summary, CCL2 and Fsp1 
expression in IDC does not associate with patient outcome. 
Stromal CCL2 associates with decreased relapse-free survival in patients with Basal-like 
breast cancer 
 Given the heterogeneity of breast cancer, and some associations with hormone receptor 
status, it was possible that expression of CCL2 and Fsp1 proteins were associated with breast 
subtype. Therefore, we compared expression patterns of CCL2 and Fsp1 in normal breast, 
Luminal A, Luminal B, Her2+ and Basal-like breast cancers.  Luminal A breast cancers were 
identified as ER+ and/or PR+, Her2- and low Ki67 (<14%) or mitotic index (<2). Luminal B 
breast cancers were defined by expression of ER and/or PR, expression of Her2+ and high Ki67 
(>14%) or mitotic index (>2).  Her2+ breast cancers were identified as ER-, PR- and strongly 
Her2+, while Basal-like breast cancers were defined by the absence of ER, PR and Her2 
expression (46-49).   
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    Luminal A, Luminal B and Basal-like breast cancers showed significantly higher levels of 
CCL2 and Fsp1 expression in whole tissues, compared to normal breast tissues (Figure 6A).  
There were no significant differences in epithelial CCL2 and Fsp1 expression among the 
different tissue types (Figure 6B). We observed a significant increase in expression of stromal 
CCL2 and stromal Fsp1 in Luminal A, Luminal B and Basal-like breast cancers (Figure 6C), 
compared to normal breast tissues. These data indicate that a significant source of CCL2 and 
Fsp1 expression originated from the stroma among the different breast cancer subtypes. 
    CCL2 and Fsp1 were further analyzed for associations with patient outcome among the 
different breast cancer subtypes.  By univariate Cox Regression Analysis, expression of CCL2 
and Fsp1 proteins in whole tissues, stroma or epithelium were not associated with outcome of 
patients with Luminal A, Luminal B or Her2 overexpressing breast cancers (Table 6).  For 
patients with Basal-like breast cancer, total and stromal Fsp1 expression were marginally 
associated with decreased overall survival, by univariate Cox Regression analysis (Table 7), but 
did not show any significant associations with patient outcome when adjusted for multiple 
factors (Table 8 and 9). By univariate and multivariate Cox Regression analyses, stromal CCL2 
was associated with decreased recurrence free survival of patients with Basal-like breast cancer 
(Table 10). Furthermore, stromal CCL2 (HR= 7.51 p=0.007) was associated with a greater 
hazard than cancer stage (HR=2.54, p=0.045) and tumor grade (HR=0.41, p=.0871) (Table 10). 
We also found that chemotherapy treatment was associated with a higher hazard than the absence 
of chemotherapy, a trend that was also reported in previous studies (56). In summary, these data 
demonstrate that stromal CCL2 expression is associated with decreased recurrence free survival 




Figure 6. Associations of CCL2 and Fsp1 proteins with molecular subtypes. Expression 
levels of CCL2 and Fsp1 in whole tissue (A), epithelium (B) and stromal(C) were examined in: 
normal breast tissues (n=20), Luminal A (n=135), Luminal B (n=113), Her2+ (n=42) or Basal-
like (n=75) breast cancers. Statistical analysis was performed using Kruskal-Wallis Test with 
Dunn’s post-hoc comparison. Statistical significance was determined by p<0.05; *p<0.05, 
**p<0.01, ***p<0.001, n.s. = not significant. 
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Table 6. Associations of CCL2 and Fsp1 expression with outcome for patients with  
Luminal A, Luminal B or Her2+  breast cancers. Associations of CCL2 and Fsp1 with overall 
survival and recurrence free survival were determined using univariate Cox Regression analysis. 
95% confidence interval (CI) of the calculated Hazard Ratio (HR) is shown. Statistical  
significance was determined by p<0.05. 
 
 Factor 
Overall survival   Recurrence free survival 
HR 95% CI p-value   HR 95% CI p-value 
 
CCL2 total 0.02 0.00 32455.83 0.582 
 
0.02 0.00 5081.37 0.535 
 
CCL2 stromal 
0.33 0.01 11.45 0.538 
 
1.39 0.10 19.65 0.806 
LumA CCL2 epithelial 
0.62 0.00 2208.55 0.908 
 
0.05 0.00 250.25 0.493 
 
Fsp1 total 1.60 0.19 13.51 0.665 
 
1.13 0.15 8.49 0.903 
 
Fsp1 stromal 
0.68 0.07 6.21 0.729 
 
0.52 0.06 4.24 0.543 
 
Fsp1 epithelial 
1.99 0.23 16.90 0.529   2.41 0.35 16.61 0.371 
 
CCL2 total 0.02 0.00 116.90 0.369 
 
0.01 0.00 48.28 0.269 
 
CCL2 stromal 
0.59 0.10 3.68 0.575 
 
0.54 0.09 3.25 0.499 
LumB CCL2 epithelial 
0.03 0.00 11.69 0.253 
 
0.03 0.00 8.67 0.230 
 
Fsp1 total 0.76 0.11 5.25 0.779 
 
0.83 0.13 5.47 0.844 
 
Fsp1 stromal 
0.92 0.13 6.32 0.932 
 
0.73 0.11 4.85 0.743 
 
Fsp1 epithelial 
0.40 0.07 2.40 0.317 
 
0.70 0.13 3.86 0.684 
 
CCL2 total 0.00 0.00 904.47 0.235 
 
0.00 0.00 700.93 0.269 
 
CCL2 stromal 
1.01 0.06 18.43 0.993 
 
9.17 0.24 350.51 0.233 
Her2+ CCL2 epithelial 
0.01 0.00 427.02 0.372 
 
0.01 0.00 214.89 0.352 
 
Fsp1 total 0.15 0.01 1.98 0.151 
 
0.30 0.03 3.36 0.328 
 
Fsp1 stromal 
0.16 0.01 2.39 0.183 
 
0.39 0.03 5.59 0.485 
 
Fsp1 epithelial 0.37 0.03 5.11 0.459 
 
0.42 0.03 5.04 0.490 




Table 7. Associations of CCL2 and Fsp1 expression with patient outcome in Basal-like 
breast cancers. Associations of CCL2 and Fsp1 with overall survival and recurrence free 
survival were determined using univariate Cox Regression analysis. 95% confidence interval 




Overall survival   Recurrence free survival 
HR 95% CI p-value   HR 95% CI p-value 
CCL2 total 0.05 0.00 764.46 0.544 
 
0.06 0.00 1103.32 0.573 
CCL2 stromal 1.61 0.55 4.76 0.386 
 
5.28 1.31 21.25 0.019 
CCL2 epithelial 0.02 0.00 69.49 0.333 
 
0.01 0.00 38.31 0.246 
Fsp1 total 0.13 0.02 1.19 0.071 
 
0.28 0.04 2.31 0.239 
Fsp1 stromal 0.15 0.02 1.31 0.086 
 
0.31 0.04 2.28 0.250 
Fsp1 epithelial 0.36 0.03 4.16 0.417   0.66 0.06 7.27 0.734 
Table 7. Associations of CCL2 and Fsp1 expression with patient outcome in Basal-like breast cancers 
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Table 8. Univariate and Multivariate Cox Regression Analyses on the association of total 
Fsp1 expression with overall survival in patients with Basal-like breast cancers. 95% 
confidence interval (CI) of the calculated Hazard Ratio (HR) is shown. Statistical significance 





HR 95% CI p-value 
 
HR 95% CI p- value 
Age 1.00 0.97 1.02 0.636 
 
-     
 Stage 
   
 
    
 
    II 1.00     
0.082  
1.00     
0.738 
    III 1.81 0.93 3.53 
 
1.132 0.546 2.347 
Grade 
   
 
    
 
    I 0.00 0.00 
 0.871  
-   
 
  
    II 1.00 




    III 0.83 0.41 1.67 
 
-     
 
Chemotherapy 
   
 
    
 
    No 1.00 
  0.050  
1.00 
  0.117     Yes 2.29 1.00 5.25 
 
2.103 0.829 5.33 
Radiation therapy 
   
 
    
 
    No 1.00 
  0.060     0.081     Yes 1.94 0.97 3.85 
 
1.974 0.919 4.238 
Hormone therapy 
   
 
         No 1.00 
  0.953  
- 
       Yes 1.06 0.15 7.77 
 
-     
 Fsp1 total 0.13 0.02 1.19 0.071 
 
0.196 0.02 1.909 0.160 




Table 9. Univariate and Multivariate Cox Regression Analyses on the association of stromal 
Fsp1 expression with overall survival in patients with Basal-like breast cancers. 95% 
confidence interval (CI) of the calculated Hazard Ratio (HR) and p-value is shown. Statistical 






HR 95% CI p- value 
 
HR 95% CI p- value 
Age 1.00 0.97 1.02 0.636 
 
-     
 Stage 
   
 
    
 
    II 1.00     
0.082 
 
1.00     
0.567 
    III 1.81 0.93 3.53 
 
1.26 0.57 2.78 
Grade 
   
 
    
 
    I 0.00 0.00 
 0.871  
-   
 
  
    II 1.00 




    III 0.83 0.41 1.67 
 
-     
 
Chemotherapy 
   
 
    
 







    Yes 2.29 1.00 5.25 
 
4.19 1.23 14.25 
Radiation therapy 
   
 
    
 







    Yes 1.94 0.97 3.85 
 
1.64 0.71 3.76 
Hormone therapy 
   
 
         No 1.00 
  0.953  
- 
       Yes 1.06 0.15 7.77 
 
-     
 Fsp1 stromal 0.15 0.02 1.31 0.086 
 
0.26 0.03 2.47 0.241 




Table 10.  Univariate and multivariate Cox Regression analyses on the association of 
stromal CCL2 expression with recurrence free survival of patients with Basal-like breast 
cancers. Association of CCL2 and recurrence free survival was determined by Cox univariate or 
multi-variate regression analysis. Hazard Ratio (HR), 95% confidence interval (CI) of the 






HR 95% CI p-value 
 
HR 95% CI p-value 
Age 0.99 0.96 1.01 0.242 
 
-     
 
Stage 
   
 
 
       
    II 1.00     
0.065  
1.00     
0.048 
    III 1.88 0.96 3.67 
 
2.45 1.01 5.95 
Grade 
   
 
    
 
    I 0.00 0.00 0.00 
0.958  
-   
 
  
    II 1.00 




    III 0.90 0.44 1.84 
 
-      
Chemo-therapy 
   
 
    
 








3.73 1.10 12.58     Yes 2.98 1.23 7.19 
Radiation therapy 
   
 
         No 1.00 
  0.102  
- 
       Yes 1.80 0.89 3.62 
 
-     
 
Hormone therapy 
   
 
         No 1.00 
  0.656  
- 
       Yes 0.82 0.34 1.98 
 
-     
 
CCL2 stromal 5.28 1.31 21.25 0.019 
 
7.51 1.72 32.91 0.007 






 Despite the importance of the stroma in animal models of breast cancer, the use of 
stromal biomarkers in the clinical setting remains to be validated. In these studies, we report that 
stromal CCL2 expression correlates with worse relapse-free survival in Basal-like breast cancer 
and was independent of stromal Fsp1 or other commonly recognized prognostic factors such as 
grade.  
     While CCL2 is expressed in the stroma and epithelium of breast tissues, and significantly 
correlates with Fsp1 expression in the overall cohort, we show that only stromal CCL2 is a 
significant prognostic factor in recurrent Basal-like breast cancers. We did not observe a 
significant association between CCL2 expression in whole tissues, stroma or epithelium with 
patient outcome in the overall cohort. These studies contrast with previous studies showing that 
CCL2 expression correlated with poor patient prognosis regardless of molecular subtype (35,52).  
It is possible that different experimental designs contributed to the different results. We utilized 
an Image J software approach to quantify protein expression in patient samples collected from 
US patients (n=427). Previous studies utilized smaller sample sizes (n=128-150), collected from 
Japanese patients (35,52). One study used an ELISA approach to analyze breast tumor samples 
(52). Another study relied on visual scoring of samples during immunohistochemistry analysis 
(35). It is possible that regional differences affect expression of CCL2 in patients. It would be of 
interest in the future to determine whether demographics affect CCL2 expression in cancer 
patients.  
     Interestingly, we observed that high level CCL2 expression in the overall cohort was 
inversely associated with T stage or N stage, which would be associated with good prognosis. In 
contrast stromal CCL2 expression was associated with poor prognosis in patients with Basal-like 
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breast cancer. We noted that a large number of cases in the overall cohort were Luminal A and B 
breast cancer, (n= 248) compared to Basal-like breast cancers which were mainly stage III breast 
cancers (n=75).   Patients with Luminal breast cancer show a more favorable prognosis than 
Basal-like breast cancer (46,47). Thus, the discrepancy may be due to the large proportion of 
Luminal breast cancer cases, which were consistent with the overall diagnostic trends in the US 
(57,58), but may have skewed the associations of CCL2 in the overall cohort. While CCL2 
expression was not significant in Her2+ breast cancers in our studies, a recent study of 32 Her2+ 
breast cancer patients reported that high levels of serum CCL2 associated with favorable 
outcome in patients vaccinated against Her2 antigen (59).  High CCL2 expression could predict a 
more favorable outcome if examined in a therapeutic context. These studies suggest different 
complex roles for CCL2 among different subtypes of breast cancer.  
     In addition to fibroblastic cells, CCL2 was expressed in infiltrating cells in our patient 
samples, consistent with previous studies [32, 35].  It is likely that fibroblasts and macrophages 
together, constitute a major source of CCL2 expression in breast cancer stroma. Despite the 
similarities in expression patterns, stromal CCL2 but not stromal Fsp1, was associated with 
decreased recurrence free survival of Basal-like breast cancer patients. We observed a small but 
not statistically significant association between total Fsp1 (HR=0.13, p=0.071) and stromal Fsp1 
expression (HR=0.15, p=0.086) with favorable overall survival, opposite results of stromal 
CCL2.  These results further suggest that stromal CCL2 expression is independent of Fsp1 
expression in Basal-like breast cancers. These results are consistent to one recent study reporting 
that high expression of Fsp1 in the stroma correlated with favorable overall survival and 
increased relapse-free survival in the overall cohort in univariate analyses (60).   
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     In summary, our studies demonstrate an association between poor outcome in Basal-like 
breast cancer and CCL2 expression in the stroma. These studies demonstrate that stromal 







Chapter III: Function of the CCL2/CCR2 signaling in fibroblasts and breast 
cancer cells interaction 
 




Introduction   
 Stromal CCL2 expression correlated with poor prognosis for patients with basal-like 
breast cancers (61). In animal models, antibody neutralization of CCL2 inhibits growth and 
metastasis of breast tumor xenografts correlating with decreased macrophage recruitment 
(35,36,38). While the majority of studies on CCL2/CCR2 signaling in breast cancer have focused 
on its role in regulating immune cell recruitment, recent studies have suggested an immune 
independent function for CCL2/CCR2 signaling. CCR2 is overexpressed in breast cancer cells, 
and is important for CCL2 induced cell motility and survival (39).  CCL2 neutralization inhibits 
fibroblast induced tumor cell invasion (62). While CCL2 may be overexpressed in the tumor 
(35,61), these studies suggest that CCL2/CCR2 signaling to breast cancer cells mediated by 
fibroblasts may play an important role in breast cancer progression, independent of the immune 
system. 
     In these studies, we sought to characterize the role of autocrine and paracrine 
CCL2/CCR2 signaling in progression of basal-like breast cancers using the MCF10CA1d 
xenograft mouse models (63,64). Co-grafting MCF10CA1d breast cancer cells with cancer 
associated fibroblasts enhanced breast tumor growth, which was abrogated by knockdown of 
CCL2 in the stroma or knockout of epithelial CCR2. The reduction in breast tumor growth was 
independent of macrophage recruitment or tumor angiogenesis. Knockout of CCR2 alone had 
minimal effects on cancer cells survival or proliferation, but ablated stromal conditional medium 
or recombinant CCL2 induced proliferation. The SRC or PKC pathways activated by CCL2 
signaling contributed to CCL2/CCR2 mediated growth of breast cancer cells. Comparison among 
different molecular subtypes through datamining revealed CCL2 and CCR2 were most highly 
expressed in basal-like breast cancers. These studies reveal fibroblasts are an important source of 
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CCL2 production, and regulate basal-like breast cancer growth through CCL2/CCR2 signaling in 
breast cancer cells. Thus, the CCL2/CCR2 signaling may serve as potential therapeutic targets in 
basal-like breast cancer. 
Materials and methods   
Cell lines and culture 
 The human breast cancer cell line MCF10CA1d (63,64) was kindly provided by Fred 
Miller, Ph.D. (University of Michigan). MCF10A-DCIS.com was kindly provided by Fariba 
Behbod, Pharm. D., Ph.D. (University of Kansas Medical Center). BT-20, MDA-MB-436, 
MDA-MB-468 and HCC1937 were kindly provided by Roy Jensen, M.D. (University of Kansas 
Medical Center). MDA-MB-231was purchased from ATCC. MDA-MB-436 was cultured in 
Leibovitz’s L-15 medium, supplemented with 10% fetal bovine serum (FBS). MDA-MB-436 
was cultured in L-15 medium, supplemented with 10%FBS, 10 ug/ml insulin and 16 ug/ml 
glutathione. BT-20 cells were cultured in Eagle’s Minimal Essential Medium and supplemented 
with 10%FBS. All other cell lines were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 10% FBS, 2mM L-glutamate and 1% penicillin-streptomycin. Primary 
human breast cancer fibroblasts (CAF) and normal adjacent fibroblasts (NAF) were obtained 
from invasive breast carcinoma tissue samples obtained from University of Kansa Medical 
Center Biospecimen Repository. Mouse mammary fibroblasts were derived from MMTV-PyMT 
transgenic mice (65), or tumor- free mice. Fibroblasts were isolated from tissues as previously 
reported (66). Purity of fibroblasts was assessed by DNA genotyping and for positive expression 
of Fsp1, a-SMA and N-cadherin, but absence of other cell lineage markers. Fibroblasts were 
immortalized by transfection of hTert prior to ablation studies, using approaches previously 
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described (67). All cell lines were confirmed mycoplasma free using the mycoplasma detection 
kit (Lonza, #LT07-703). 
Orthotopic transplantation tumor model 
     Female athymic nude mice (FoxN1nu/nu) 6-8 weeks old were purchased from Charles 
River.  Breast cancer cells and fibroblasts were orthotopically transplanted using approaches 
previously reported (68). Briefly, 100,000 cancer cells and 250,000 fibroblasts were seeded into 
50 ul Rat Tail Collagen type I overnight. In cancer cell graft alone, only 10^5 cancer cells were 
used. Mice were anesthetized with 1-3% isoflurane. An incision was made into the skin flap to 
expose the #4-5 mammary glands. A pocket was made underneath the mammary lymph node 
using spring scissors and the collagen plug was inserted into the pocket.  Wounds were closed by 
gut absorbable suture. Mice were monitored twice a week. Mice were sacrificed at 
approximately 6 weeks of age when the control tumors grew 1.5 cm in diameter, the largest 
allowable size allowed by the Institutional Animal Care and Use Committee (IACUC). All 
animal procedures were approved by IACUC under AAALAC guidelines. 
Lung whole mount staining 
     Lung metastasis was analyzed by lung whole mount staining as reported before (69). 
Briefly, lungs were fixed in 10% neutral formalin overnight, dehydrated through 70%, 95% and 
100% ethanol, and cleared in xylene overnight in 4oC. Lungs were then rehydrated through 
ethanol gradients, stained with hematoxylin for 10min, and de-stained with 1%HCL in water for 




     10^4 human or mouse fibroblasts were seeded overnight into 24-well plate, and changed 
into serum free DMEM medium for 24h. Conditioned medium was assayed for human CCL2 
(Peprotech, #900-K31) or murine CCL2 expression (Peprotech, #900-126) 
shRNA knockdown 
     Stable cell lines were generated by transduction of lentivirus expressing shRNA. 
Lentivirus was produced by co-transfection of shRNA and packaging vectors (psMD2.G and 
psPAX2) into HEK293T cells, using methods previously described (70). Lentiviral vectors were 
obtained from Origene with shRNA targeting sequence as follows. murine CCL2 (TL501987): 
5’-ACGTGTTGGCTCAGCCAGATGCAGTTAAC-3’, human shRNA1: 5’-
TATAGAAGAATCACCAGCAGCAAGTGTCC-3’, human shRNA2:5’- 
AGAAGCTGTGATCTTCAAGACCATTGTGG-3’. Scramble control shRNA (TR30021) 
sequence was not provided. 
CRISPR/Cas9 gene ablation 
     Lentivirus vector expressing Cas 9 and blasticidin selection marker was obtained from 
Jeremy Chien, Ph.D. (University of Kansa Medical Center), originally developed by Feng 
Zhang, Ph.D. (MIT)(71). Guide RNA (gRNA) for human CCL2 was: 5’-
GTACCTGGCTGAGCGAGCCCT-3’. gRNA for CCR2 was 5’- 
TTCACAGGGCTGTATCACAT-3’ . For CCL2 gene ablation, the gRNA for human CCL2 was 
cloned into the lentivirus vector pLKO5.sgRNA.EFS.GFP (72) (Addgene, #57822) using BsmBI 
restriction enzymes. Fibroblast cells were transduced with Cas9 lentivirus one time, treated with 
4 ug/ml blasticidin (Invitrogen, #R210-01), followed by transduction with lentivirus expressing 
gRNA or empty vector. Cells were sorted by flow cytometry for GFP and were cultured in a 96 
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well plate seeded at 0.5 cell per well.  For CCR2 gene ablation, the gRNA was cloned into the 
pL-CRISPR.EFS.GFP vector (72) (Addgene, #57818), a lentivirus vector containing both the 
Cas9 and GFP reporter, using BsmBI restriction enzyme. MCF10CA1d Cells were transduced 
with the lentivirus one time, flow sorted by GFP and seeded into 6-well plates at 1000 cells per 
well. Individual colonies were manually picked and seeded into a 96-well plate. Colonies were 
screened for CCR2 gene alternation by PCR with primers flanking the targeting site: Forward 5’- 
ACATGCTGGTCGTCCTCATC-3’, Reverse 5’-: AAACCAGCCGAGACTTCCTG-3’. PCR 
was performed at annealing temperature of 67oC for 30 cycles with 20 ng genomic DNA 
templates. DNA from mutant clones was further confirmed by sequencing (GENEWIZ).  
Flow cytometry 
    Adherent cells were lifted off plates using Accutase (Millipore Sigma, #SCR005) at 
370C. Cells were washed in PBS, incubated with anti-CCR2-PE at a 1:10 dilution (R&D 
Systems, #FAB151P) for 1 hour. Cells were washed in PBS and read by flow cytometer using a 
BD LSRII instrument.  
Generation of conditioned medium: 
     1 million cancer cells or fibroblasts were seeded into a 10 cm dish in DMEM/10% FBS. 
Medium was collected after 24h, centrifuged and filtered through 0.45um to eliminate cell debris 
before use. 
2D Cell proliferation assay  
     Cells were seeded overnight into a 96-well plate overnight (500 cells/well) in triplicate in 
DMEM/10% FBS. The next day, cells were incubated with fresh DMEM/10% FBS in the 
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presence or absence of: 200ng/ml human recombinant CCL2 (Peprotech, #300-04), DMSO, SRC 
inhibitor PP2 at 10uM or 20uM (AdipoGen, #AG-CRI-3563), PKC inhibitor Go6983 at 5uM or 
10 uM (Cayman Chemical, #13311). In conditioned medium studies, conditioned medium was 
used instead. Cells were fixed in 10% formalin, stained with crystal violet, extracted with 10% 
acetic acid, and quantified at OD590.  
3D spheroid assay  
     Tumor spheroids were established using conditions previously described (73). Briefly, 
96-well plates were coated with 40 ul of matrix containing 1:1 ratio of collagen (Corning, 
#354236) and Growth Factor Reduced Matrigel (Corning, #354230). MCF10CA1d cancer cells 
were seeded at 1000 cells per well in 200 ul DMEM/10%FBS containing 2.5% matrigel. The 
media was replaced with conditioned medium every 2 days for to 6 days. Bright field images of 
cell spheres were taken every two days using an EVOS FL-Auto imaging system at  10X 
magnification. Sphere size was quantified using Image J.       
Western blot 
     Cancer cells were seeded at 200,000 cells/well in a 6-well plate overnight in DMEM/10% 
FBS, serum deprived overnight, and incubated with serum free media in the presence or absence 
of 200 ng/ml recombinant human CCL2. For inhibitor studies, cells were incubated with DMSO, 
PP2 and G06983 and CCL2 together for 15 minutes. Cells were washed twice with cold PBS and 
lysed with RIPA buffer containing protease inhibitor and phosphatase inhibitors. 20-25 ug 
proteins were resolved on SDS-PAGE gels, transferred to nitrocellulose membranes. Membranes 
were blocked in 5% milk and incubated with primary antibodies at 1:1000 dilution: p-PKC (pan, 
βII Ser660, CST, #9371), p-SRC (Tyr416, CST, #6943), SRC (CST, #2123), p-AKT (Ser473, 
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CST, #4060), AKT (R&D, #MAB2053), p-ERK (Thr202/Tyr204, CST, #4370), ERK (CST, 
9107), p-SMAD3 (Ser423/425, CST, 9520), SMAD3 (CST, #9523) and ACTIN (Sigma, 
#A5441).  Corresponding HRP conjugated secondary antibodies (anti-mouse or anti-rabbit) at 
1:2000 dilution were used.    
Histology/immunohistochemistry 
     Tumor samples were fixed in 10% formalin overnight, paraffin embedded and sectioned 
at 5- micron thickness. For H&E stain, sections were incubated in hematoxylin for 3 minutes and 
counter stained with eosin for 3 minutes. For immunostaining, sections were heated in 10mM 
sodium citrate at low pressure for 20 minutes using a pressure cooker to de-crosslink antigens. 
Peroxidases were quenched in water containing 10% methanol and 10% hydrogen peroxidase. 
Slides were blocked in PBS containing 5% FBS for 1 hour, incubated at 1:100 dilution with 
primary antibodies: anti-human cytokeratin 5 (ThermoFisher, #MA5-12596), Ki67 (Santa Cruz, 
#sc15402), cleaved Caspase-3 (CST, #9661), von William Factor (Chemicon, #AB7356), 
Arginase I (Santa Cruz, #sc-20150), LC3b (CST, #3868). Samples were stained with 
corresponding biotinylated anti-rabbit or anti-mouse secondary antibodies at 1:500 dilution.  
Sections were incubated with streptavidin-HRP (Vector Lab., #PK-6100). Antigens were 
detected using DAB substrate (Vector Lab., #SK-4100). Slides were counter-stained with 
hematoxylin, dehydrated and mounted with Cytoseal (Thermo Fisher, #348976). Images were 
captured using EVOS FL-Auto microscope, 4 random images at 100 or 200x magnification. 




     Datasets were downloaded from cBioportal (http://www.cbioportal.org/). The TCGA 
dataset (74)(n=825) and the METABRIC dataset (75,76) (n=2509) were analyzed for CCL2 and 
CCR2 expression. Breast cancer subtype was defined by PAM50.   
Statistical analysis  
     Statistical analysis was performed using GraphPad software. Two tailed Student T test 
was used for two group comparison. One Way ANOVA with Bonferroni post-hoc comparison 
was used for multiple group comparison. Correlation of CCL2 and CCR2 expression was 
analyzed using Pearson’s correlation test. Statistical significance was determined by p<0.05.   
Results   
Fibroblast mediated growth of basal-like breast tumor xenografts correlates with CCL2 
expression 
 In recent studies, we demonstrated that CCL2 expression in breast cancer stroma 
correlated with accumulate of fibroblastic cells, and was associated with poor prognosis for 
patients with basal-like breast cancer (61). To further understand the role of CAF derived CCL2 
on progression of basal-like breast cancers, we isolated multiple primary CAFs from human 
breast cancer biopsy and mouse mammary tumors. Characterization of those fibroblasts 
confirmed they expressed fibroblast markers Fsp1, a-SMA and N-cadherin, but lacked 
expression markers of other cell lineages (Figure 7). Examination of chemokine CCL2 
expression by ELISA revealed both human and mouse fibroblasts expressing higher level of 
CCL2, compared to common breast cancer cell lines and normal breast epithelial cell line 





Figure 7. Molecular characterization of CAFs and CCL2 expression. Immunohistochemistry 
staining of mouse mCAF-1 (A) and human hCAF-1 (B) using markers of mesenchymal (Fsp1, N-
Cadherin, a-SMA), epithelial (E-cadherin, pan-cytokeratin) or endothelial (VEGFR2) lineages and 
CCL2. (C) CCL2 expression determined by ELISA in various human breast cancer cell lines or 
normal epithelial cell (MCF10A). Condition medium was collected from 5*10^4 cells. hCAF-1 was 
used for comparison.   




Figure 8. Breast cancer associated fibroblasts with high CCL2 expression promoted 
CA1D tumor growth.  (A) Human CCL2 expression level in primary breast cancer 
associated  fibroblasts (CAF) and normal fibroblasts (NAF) determined by ELSIA per 
10^4 cells. (B) Mouse CCL2 expression in CAFs and NAF, serum free medium (SF) used 
as control. Tumor weight of CA1D cancer cells co-grafted with human CAFs or NAFs(C), 
or mouse CAFs or NAFs (D), compared with cancer cell alone after four weeks 
inoculation. Each dot represents one mouse, and representative tumor images were shown 
above. Scale bar=1cm. One way ANNOVA was used for statistical analysis. *p<0.05, 
**p<0.01.  
Figure 8. Breast cancer associated fibroblasts with high CCL2 expression promoted CA1D tumor growth 
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human samples. We co-transplanted human or mouse fibroblasts with the human basal breast 
cancer cell line MCF10CA1d, which was derived from Ras transformation of MCF10A breast 
epithelial cells (63,64). Co-transplantation with human fibroblasts revealed that CAF-1 and 
NAF-3 significantly increased primary tumor growth over MCF10CA1d alone, correlating with 
high CCL2 expression (Figure 8A-B). Similarly, murine CAF-1 significantly increased the 
growth of primary MCF10CA1d xenografts, correlated with a high murine CCL2 expression 
(Figure 8B and D).  Histological analysis revealed that grafting of tumor cells alone or with 
fibroblasts resulted in formation of high grade, invasive tumors with few glandular structures 
(Figure 9A). The majority of the tumor tissue was comprised of CK5+ breast epithelial cells 
(Figure 9B), consistent with cytokeratin expression of basal-like breast cancers (6). Grafting of 
MCF10CA1d cells alone or with fibroblasts did not result in macroscopic lung metastasis as 
determine whole mount staining (Figure 9C).  In summary, these data indicate that CAFs 
increase tumor growth but do not significantly affect metastasis of MCF10CA1d tumor 
xenografts. 
Ablation of stromal CCL2 expression inhibits growth and survival of basal-like breast 
tumor xenografts  
In previous studies, we found that CCL2 was expressed in both the tumor epithelium and stroma 
(61). To determine the functional contribution of CCL2 on primary tumor growth, we examined 
the effects of CCL2 deficiency in fibroblasts and MCF10CA1d cells. CCL2 was knocked out in 
human CAFs (hCAF-1) by CRISPR/Cas9 (77) through targeting N-terminal of CCL2 protein 
(Figure 10A). Two CCL2 deficient clones (mut-7, mut-22) were generated and determined by 
ELISA (Figure 10A). Control or CCL2 deficient fibroblasts were then co-grafted with 




Figure 9. Histology and cancer cells identification in the co-graft tumor model. 
Tumor sections from CA1D or CA1D+hCAF-1 stained with hematoxylin-eosin (A), and 
immunohistochemistry stained with human specific cytokeratin 5 (CK5) (B). (C) 
Examples of lung micro-metastasis by lung  whole amount staining. Scale bar is 200 um. 
 




Figure 10. CCL2 derived from cancer associated fibroblasts contributed to CA1D 
tumor growth. (A) CCL2 expression in human CAF-1 with targeted mutation by 
CRISPR/Cas9. Arrow indicates gRNA target site in the first coding exon (red). CCL2 
expression from mutant clones (7# and 22#) was compared to control clone or parental 
cell line (par). (B) Tumor weight of CA1D co-grafted with control or CCL2 mutant CAF-
1 after 6 weeks inoculation. (C) Scheme of CCL2 knockdown in mouse CAF-1 or CA1D 
cells. Tumor weight of co-graft model with CCL2 knockdown in mCAF-1 (shCcl2) or 
CA1D cancer cells (shCCL2-1 and shCCL2-2). Each group was compared to control 
shRNA (CR) in  mCAF-1 and CA1D. Tumor was grafted for four weeks, with five mice 
per group. One way ANNOVA was used for statistical analysis. *p<0.05, **p<0.01, 
***p<0.001, n.s. p>=0.05. Determination of CCL2 knockdown efficiency in mCAF-1 (D) 
or human CA1D (E) determined by mouse or human CCL2 ELISA. CCL2 expression 
level was normalized to parental or control shRNA.  
Figure 10. CCL2 derived from cancer associated fibroblasts contributed to CA1D tumor growth 
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hCAF-1 clones resulted in a significant decrease in tumor growth over time compared to co-
grafting with control hCAF-1 cells (Figure 10B). To further confirm this study, CCL2 expression 
was knocked down in murine CAF-1 (mCAF-1) and in MCF10CA1d breast cancer cells by 
stable shRNA expression. This resulted in a 60-80% decreased in CCL2 expression in mCAF-1 
(Figure 10C) or MCF10CA1d cells (Figure 10D) compared to control shRNA cells. Breast 
cancer cells co-grafted with CCL2 deficient mCAF-1 cells showed a significant decrease in 
tumor mass compared to co-grafting with control CAF-1 cells, while CCL2 deficient 
MCF10CA1d cells co-grafted with control mCAF-1 did not (Figure 10E). Co-grafting with 
CCL2 deficient MCF10CA1d cells with CCL2 deficient CAF-1 cells did not further affect tumor 
mass (Figure 10E). These data indicate that CCL2 derived from murine CAFs but not from 
MCF10CA1d cells is important for primary tumor growth.  In summary, our studies demonstrate 
that CCL2 derived from fibroblasts regulate breast cancer growth.   
     We further evaluated the effects of stromal CCL2 ablation on the primary tumor 
proliferation and survival through histology. By H&E stain, MCF10CA1d tumors co-grafted 
with control or CCL2 shRNAs fibroblasts both showed significant areas of central necrosis. 
Quantification of these areas revealed no significant differences in necrosis between the groups 
(Figure 11A). By immunohistochemistry, stromal CCL2 deficiency did not significantly affect 
tumor cell proliferation as indicated by PCNA staining (Figure 11B), but did significantly 
increase cleaved caspase-3 expression and LC3B immunostaining, indicating increased apoptosis 
and autophagy (Figure 11C-D). While CCL2 is known is associated with increased levels of M2 
macrophages (69) and tumor angiogenesis (78), there were no significant changes in M2 
macrophage levels or blood vessel density in the primary tumor, as determined by 
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immunostaining for arginase I and VWF8 (Figure 12A-B). These data indicate that stromal 
CCL2 mediated tumor growth  
  
Figure 11. CCL2 knockdown in cancer associated fibroblasts associated with 
increased expression of apoptosis and autophagy markers. Comparison of necrosis 
by hematoxylin-eosin staining (A) or molecular markers between CA1D co-grafted 
with control (CR) or CCL2 knockdown(shCcl2) mouse CAF-1 by  
immunohistochemistry with PCNA (B), LC3b (C) and cleaved caspase-3 (D). 
Necrosis area in (A) were circled by dotted white line. Inserts in B-D showed the 
magnified picture of staining. Scale bar represented 400 um. Student T test was used 
for statistical analysis. *p<0.05, **p<0.01, and n.s. (p>=0.05).  
Figure 11. CCL2 knockdown in cancer associated fibroblasts associated with increased expression of 




Figure 12. CCL2 knockdown in cancer associated fibroblasts did not significantly affect 
M2 macrophage infiltration and angiogenesis. Comparison of stromal cell markers between 
CA1D co-grafted with control (CR) or CCL2 knockdown(shCcl2) mouse CAF-1, using M2 
macrophage marker Arginase I (A) and angiogenesis marker vWF (B). Student T test was used 
for statistical analysis. n.s. (p>=0.05).  




is associated with cell survival, and is independent of tumor angiogenesis and macrophage 
recruitment. 
CCL2 derived from fibroblasts signals directly to breast cancer cells to mediate cell growth 
 To determine whether CCL2 derived from CAFs directly signaled to breast cancer cells, 
we utilized in vitro cell culture systems. MCF10CA1d breast cancer cells cultured in a 
monolayer were treated with conditioned medium from hCAF-1 cells or recombinant CCL2, and 
showed a significant increase in cell density as determined by crystal violet staining (Figure 
13A-B). Interestingly, CCL2 mediated cell growth was associated with the serum concentration 
used for incubation, as treatment of breast cancer cells with CCL2 in 1% FBS resulted in a small 
but not significant increase in cell density (Figure 13B). 3-dimensional (3D) cultures were used 
to more closely mimic conditioned in tumor tissues (73). Similar to 2D culture, MCF10CA1d 
cells treated with fibroblast conditioned medium showed an increase in spheroid growth over 
time (Figure 13C-D). MCF10CA1d spheroids treated with conditioned medium from CCL2 
deficient hCAF-1 cells resulted in significantly decreased spheroid size over time, compared to 
control hCAF-1 cells (Figure 13E). The effect of CCL2 deficient fibroblast condition medium 
can be rescued by adding back of recombinant CCL2 (Figure 13F). These data indicate that 
CCL2 derived from fibroblasts acts directly on MCF10CA1d breast cancer cells to mediate 
growth over time.  
CCR2 knockout inhibits CCL2 mediated breast cancer growth 
 In previous studies, we showed that CCR2 was overexpressed in breast cancer cells, 





Figure 13. CCL2 derived from cancer associated fibroblasts promoted 
MCF10CA1d growth in vitro. (A) Comparison of CA1d cell proliferation in 2-
dimensional culture in regular medium (10%FBS), or in condition medium from CA1d 
(CM-CA1D) or human CAF-1 (CM-hCAF-1) . Cell number was quantified by crystal 
violet staining. (B) Effect of recombinant CCL2 (200 ng/ml) in CA1d cell proliferation 
in 2D in different serum medium. (C) Representative images of CA1d spheres in 3-
dimensional culture for 6 days. Comparison of CA1d sphere size during 8-day 3-
dimensional culture in conditional medium (D), CCL2 mutant fibroblasts condition 
medium(7# and 22#) (E) or mut-7# fibroblasts condition medium with added 
recombinant CCL2 (200 ng/ml) (F).  One way ANNOVA was used for statistical 
analysis. *p<0.05, **p<0.01, ***p<0.001, n.s. p>=0.05.  
 
Figure 13. CCL2 derived from cancer associated fibroblasts promoted MCF10CA1d growth in vitro 
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 To further determine the significance of epithelial CCR2 expression to CAF mediated breast 
tumor growth, we knocked out CCR2 in MCF10CA1d breast cancer cells by CRISPR/Cas9, 
targeting the third transmembrane domain of CCR2 protein (Figure 14A). PCR screening 
identified two mutant clones F1 and G10, both of which possessed deletion and/or insertion in 
the coding region and resulted frame shift of the CCR2 protein (Figure 14B-C). Flow cytometry 
analysis of cell surface receptor expression indicated a 75 % reduction in CCR2 expression in the 
G1 mutant, while the F1 mutant showed 10% reduction in CCR2 expression (Figure 15A).  It is 
likely that the F1 mutant clones expressed a truncated CCR2 protein on the membrane surface 
that may be recognized by CCR2 antibody. However, the resulting frameshift in the coding 
region generated a premature stop codon, resulting in mutants lacking a C-terminal region 
(Figure 15C). As such, we expected these mutants to abrogate CCR2 signaling, despite residual 
CCR2 expression. To control for specificity of CRISPR/Cas9 targeting, a wildtype clone (WT 
A1), which possessed an intact CCR2 gene, was identified by PCR and confirmed by sequencing 
(Figure 15B-C). Grafting of F1 or G10 cells alone showed a small but significant reduction in 
tumor growth compared to WT A1 cells. Co-grafting of F1 or G10 cells with hCAF1s resulted in 
a significant reduction in hCAF1 mediated tumor growth, compared to co-grafting of hCAF1 
with WT A1 control breast cancer cells (Figure 3-9B). The 3D culture of CCR2 deficient 
MCF10CA1d breast cancer (F1, G10) alone did not result in significant changes to spheroid size 
(Figure 15C). 2D culture of F1 or G10 cells alone did not affect cell density (Figure 3-9D). 
However, treatment of F1 or G10 cells in 3D culture with hCAF1 conditioned medium resulted 
in smaller spheroids compared to the treatment of WT A1 cells (Figure 15C).  Treatment of F1 or 
G10 cells cultured in 2D with hCAF conditioned medium showed a significant decreased in cell 
density compared to the treatment of WT A1 control cells (Figure 15D). These data indicate that 
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hCAF mediated growth of MCF10CA1d breast cancer cells through CCR2 dependent 
mechanisms. 
   
Figure 14. Screening and characterization of CCR2 mutant CA1D cell lines. (A) 
Illustration of CCR2 gRNA targeting site and PCR screening method. Red asterisk 
indicated the gRNA target site. (B) Identification of CCR2 mutant CA1D cell lines by 
PCR screening of genomic DNA from different cell colonies, showing the DNA size shift 
of mutant clone G10 and F1 compared to parental cell line or wildtype clone A1. (C) 
DNA sequence detail of CCR2 mutant F1 and G10 clones. CCR2-A CDS sequence was 
used as reference to detail mutation sites. Note the gRNA target region in on common 
region of CCR2-A and CCR2-B, so both isoform will be mutated. The mutated CCR2 
protein sequence was predicted from the DNA sequence. 
 
Figure 14. Screening and characterization of CCR2 mutant CA1D cell lines 
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Figure 15. CCR2 mutant CA1D cancer cells lost response to CCL2 stimulated tumor 
progression. (A) Flow cytometry analysis of CCR2 surface expression on wildtype and 
mutant clones. Expression value is overton subtraction in population comparison. Top insert 
showed example of overlay between isotype control (blue) vs CCR2-PE (grey). (B) 
Comparison of tumor weight after grafting CCR2 mutant cancer cells alone, or in 
combination with human CAF-1 for 6 weeks in vivo. (C) Comparison of sphere growth for 
CCR2 mutants and wildtype control in response to fibroblast condition medium in 3D 
culture. (D) Comparison of cell proliferation for CCR2 mutants and wildtype control in 
response to CCL2 stimulation in 2D culture. One way ANNOVA was used for statistical 
analysis. *p<0.05, **p<0.01, ***p<0.001, n.s. p>=0.05.   
 
Figure 15. CCR2 mutant CA1D cancer cells lost response to CCL2 stimulated tumor progression 
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CCL2/CCR2 signaling mediates breast cancer growth through PKC and SRC signaling 
pathways 
 To determine the signaling mechanisms through which CCL2/CCR2 mediated breast 
tumor growth, we examined the candidate pathways observed to be regulated by chemokine 
signaling (79), including PI3K/AKT, PKC and SRC pathways. MCF10CA1d breast cancer cells 
were treated with CCL2 over time and analyzed for phosphor-protein expression by immunoblot 
analysis. CCL2 did not affect phosphor-AKT expression or SMAD3 (Figure 16). CCL2 
treatment significantly increased the level of pan phosphor-PKC (βII Ser600) and phosphor-SRC 
(Try416) expression starting at 2 min and peaking at 15 min, relative to untreated cells (Figure 
17A). CCR2 knockout inhibited CCL2 induced phosphorylation of SRC and PKC, compared to 
WT A1 cells. Interestingly, CCR2 mutants appeared to show a higher basal level expression of 
phosphor SRC and PKC, in the absence of stimulation (Figure 17B). We further confirmed by 
over-expressing CCR2 in CA1D cell lines. CCR2 over-expression was sufficient to induce SRC 
and PKC phosphorylation without CCL2 ligand treatment, and lead to increased cell 
proliferation (Figure 18A-B).             
     To determine the relevance of PKC and SRC activation to CCL2 induced cell growth, we 
treated MCF10CA1d breast cancer cells with PP2, a small chemical SRC inhibitor (80,81), or 
with the pan PKC inhibitor G06983 (82). PP2 treatment inhibited CCL2 induced phosphor-SRC 
in a dose-dependent manner (Figure 18C). G06983 treatment increased phosphor-PKC level 
(Figure 18C), which is consistent with previous studies showing that G06983 binding to PKC, 
prevented its degradation (83). PP2 or G06983 treatment over 2 days did not significantly affect 
cell density of MCF10CA1d breast cancer cells. However, after 4 days, PKC or SRC inhibition 
notably inhibited the growth of MCF10CA1d breast cancer cells  
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Figure 16. CCL2 signaling does not activate AKT and Smad3 pathways. 
Representative images showing the AKT (A), ERK/MAPK (B) and SMAD3 (C) 
pathways activation during CCL2 stimulation over 1h window time course. 
Quantification showed results from three independent results. Phosphorylation signal was 
normalized to total protein and compared to 0 min. One way ANNOVA was used for 
statistical analysis. *p<0.05, **p<0.01, ***p<0.001, n.s. p>=0.05.   
 




   
Figure 17. PKC and SRC pathways function downstream of CCL2 signaling in 
promoting CA1D cell proliferation. (A) Time course studies of SRC and PKC pathways 
activation by CCL2 stimulation (200 ng/ml) in CA1D cancer cells. (B) CCR2 mutant 
CA1D cancer cells stimulated with CCL2. (C) The effect of SRC inhibition by PP2 
inhibitor on CA1D cell proliferation during CCL2 treatment. (D) The effect of PKC 
pathway inhibition by G06983 in CA1D cell proliferation during CCL2 stimulation. One 
way ANNOVA was used for statistical analysis. *p<0.05, **p<0.01, ***p<0.001, n.s. 
p>=0.05.    




   
Figure 18. CCL2 signaling and SRC and PKC pathways. (A) The effect of CCR2 
overexpression on PKC and SRC pathways in CA1D cell lines with/without CCL2 treatment for 
15 min. (B) The effect of CCR2 over-expression in CA1D cell proliferation in 6-day time 
window. (C) Western blot examination of the effect of SRC inhibitor PP2 and PKC inhibitor 
G06983 on different dosages on p-SRC and p-PKC. Treatment was done in serum free medium 
for 15min. One way ANNOVA was used for statistical analysis. *p<0.05, **p<0.01, 
***p<0.001, n.s. p>=0.05.  
Figure 18. CCL2 signaling and SRC and PKC pathways 
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inhibited CCL2 induced growth of MCF10CA1d cells (Figure 17C-D). These data indicate that 
CCL2 mediated breast cancer cell growth through PKC and SRC dependent mechanisms. 
CCL2 and CCR2 expression are co-upregulated in basal-like breast cancers 
 In previous studies, we showed that stromal CCL2 was elevated in basal-like breast 
cancers (61). To determine the clinical significance of CCL2 and CCR2 expression, we analyzed 
cancer genomic datasets for co-expression among breast cancer subtypes. CCL2 gene 
amplification was present in about 3% patient samples across all major breast cancer datasets, 
while genetic alternations for CCR2 gene were present less than 1% (Figure 19). When we 
examined RNA expression in the TCGA dataset (74) (n=520), CCL2 and CCR2 were both 
significantly higher in basal-like subtype compared to luminal subtypes (Figure 20A). Higher 
expression of CCL2 and CCR2 in basal-like breast cancers was confirmed in a second 
independent dataset (METABRIC (75,76), n=1904) (Figure 20B).  Furthermore, CCL2 gene 
expression significantly correlated with CCR2 expression in basal-like breast cancers in the 
TCGA and METABRIC datasets (Figure 20C-D). These data indicate that CCL2 and CCR2 co-






Figure 19. Genomic alternation in CCL2 and CCR2 genes in human breast cancer 
datasets. Color coded genomic alternation frequency in human CCL2 gene (A) and CCR2 
gene (B) in breast cancer datasets. Data retrieved from cBioportal website.    
 
Figure 19. Genomic alternation in CCL2 and CCR2 genes in human breast cancer datasets 
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Figure 20. CCL2 and CCR2 are co-upregulated in basal-like breast cancer subtype. (A) 
Comparison of CCL2 and CCR2 mRNA expression among basal-like (n=96), Her2(57) and 
LumA/B (n=352) subtypes from TCGA dataset. (B) Comparison of CCL2 and CCR2 mRNA 
expression among basal-like (n=398), Her2(n=220), LumA (n=679), LumB (n=461) and normal-
like (n=140) subtypes from METABRIC dataset. (C) Pearson correlation analysis of CCL2 and 
CCR2 expression in the two datasets. 




     CCL2 is overexpressed in multiple tumor types, and is well known to regulate breast 
cancer progression through macrophage dependent mechanisms (32,33,36). While CCL2 is 
expressed in the tumor and the stroma, we report that stromal derived fibroblasts constitutes a 
major source of CCL2, and regulates the growth of basal-like breast cancers by signaling directly 
to CCR2 expressing cancer cells. Furthermore, we show that CCL2/CCR2 mediated tumor 
growth is regulated by PKC and SRC signaling pathways. As CCL2 and CCR2 are most highly 
expressed in basal-like breast cancers, the proposed pathways may represent viable therapeutic 
targets for this subtype. 
     In these studies, we noted a specific contribution from the breast CAFs in regulating 
breast tumor growth through CCL2 dependent expression. CCL2 is not confined to the stroma, 
but has been reported to be expressed in the epithelium in some breast tumors (32,33). However, 
CCL2 expression specifically in the stroma has been shown to be clinically relevant (35,61), 
correlating with poor patient prognosis for patients with basal-like breast cancers (61). The 
importance of the stroma may depend on the levels of epithelial CCL2. In these studies, we 
observed that CCL2 knockout alone in MCF10CA1d cells had minimal effects on primary tumor 
growth. However, these breast cancer cells expressed much lower levels of CCL2, compared to 
the stroma. As CCL2 knockout inhibited fibroblast mediated tumor growth, these studies indicate 
that the growth of MCF10CA1d cells may be dependent on the stroma.  Examination of tumors 
over time indicates that hCAFs appear to have the most influence on growth in the first 4 weeks. 
This may be due to a gradual recruitment of host mouse fibroblasts and macrophage, and dilution 
and disappearance of grafted fibroblasts, as was reported previously (66). While murine CCL2 
may also act on breast cancer cells to regulate cell behavior (39), host murine CCL2 from tumor-
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bearing animals was not sufficient to rescue CCL2 deficiency in grafted cancer associated 
fibroblasts. These studies thus demonstrate a key importance for human fibroblasts in mediating 
growth of breast tumor xenografts through CCL2 dependent mechanisms. 
     The MCF10 breast epithelial model system has long been used as a xenograft model of 
breast cancer progression (63,64). While hCAFs have been shown to increase invasiveness of 
other breast tumor models (38,84), hCAFs had no significant effects on local invasion or 
metastasis of MCF10CA1d breast cancer cells, potentially due to the low metastatic ability of the 
cell line (64). In our studies, we demonstrated that hCAF derived CCL2 was important for the 
growth of MCF10CA1d breast cancer cells and the less invasive derivative cell line, DCIS.com 
(63).  CCL2 had no effects on growth of other basal-like breast cancer cell lines including MDA-
MB-231 and 4T1 mammary carcinoma cells, consistent with previous studies (39). It is possible 
that CCL2 mediated growth may depend on the genetic background as MCF10CA1d and 
DCIS.com breast cancer cells were derived from in vivo selection of tumors established from 
MCF10A breast epithelial cells overexpressing HRAS, an upstream regulator of SRC-MAPK 
signaling (63). In contrast, in 4T1 and MDA-MB-231 cells, CCL2 had no effect on PKC and 
SRC phosphorylation in these studies, but was shown to activate MAPK and SMAD3 to regulate 
cellular migration in previous studies (39). These studies indicate that CCL2 effects on breast 
cancer cells may depend on the cell line and ability to activate specific pathways associated with 
cell growth or migration. Interestingly, AKT is a key pathway that regulates breast tumor 
growth, survival and invasion, and is activated by many cytokines (79). In these studies, CCL2 
had no effect on AKT phosphorylation in  MCF10CA1d, DCIS.com cell lines, although these 
cells exhibited high basal expression of phosphor-AKT, consistent with previous studies showing 
that MCF10CA1d cells possess a PI3K constitutively active mutation (H1042R) (85). CCL2 had 
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not effect on phosphor-AKT in any other breast cancer cell line (39).  In summary, these studies 
suggest that CCL2/CCR2 signaling in breast cancer cells activates a specific and unique 
combination of pathways important for growth and migration.   
 Previous studies have examined patterns of CCL2 and CCR2 expression in breast cancer, 
but have not drawn an association between these 2 genes in breast cancer subtypes. CCL2 
expression has been shown to higher in estrogen negative breast cancer compared to estrogen 
positive cancer (86). CCL2 expression in fibroblasts inversely correlated with recurrence free 
survival for patients with basal-like breast cancers (61). In other studies, CCR2 expression in 
breast cancer cells correlated with invasive potential (39). Here, in two independent breast cancer 
datasets, we show that CCL2 and CCR2 are most highly co-expressed in basal-like breast 
cancers, compared all other subtypes, revealing a new association between CCL2 and CCR2 in 
breast cancer.  
     The CCL2/CCR2 signaling pathway is currently a therapeutic target of interest due to its 
significant effects on tumor growth, survival and metastasis (32,33). Many of these effects are 
attributed to CCL2 mediated angiogenesis or macrophage recruitment.  There is currently some 
controversy to the feasibility of targeting as some studies suggest a rebound in tumor growth 
with cessation of CCL2 inhibitor treatment, due to possible macrophage dependent and 
angiogenesis feedback (87). However, this rebound may be due to the use of neutralizing 
antibodies themselves, rather than CCL2 as a target (88). Furthermore, these present studies 
indicate that targeting CCL2 or CCR2 expression may provide a particular benefit to patients 
with a basal-like subtype, where CCL2/CCR2 may signal directly to the cancer cell. Our studies 








Chapter IV: Therapeutic targeting the CCL2 signaling in breast cancer model 
 
Contents in this chapter have been published in:  
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Antibodies Elevate CCL2 Levels in Mice Bearing MCF10CA1d Breast Tumor Xenografts." 





     Neutralizing antibodies and small pharmacologic agents to target cytokines in cancer 
have proven successful for the treatment of various cancer types, including breast and lung 
cancers (89).  While small pharmacologic agents are in early clinical development (90), CCL2 
neutralizing antibodies have been the primary agent used to target CCL2 activity, and have been 
extensively studied in animal models (36,38,91,92). However, recent studies have highlighted 
certain controversies surrounding targeting of CCL2 in cancer. Delivery of CCL2 neutralizing 
antibodies in animal models of breast and prostate cancer effectively inhibited tumor growth and 
metastasis, and decreased recruitment of macrophages (36,38,91,92). However, one recent study 
showed that cessation of CCL2 neutralization in a breast cancer model, lead to a rebound in 
tumor growth, associated with increased macrophage recruitment and tumor angiogenesis in the 
primary tumor (87). In addition, clinical trials have reported limited to no therapeutic efficacy of 
the CCL2 neutralizing antibody CNTO888, either as a single agent, or in combination with 
chemotherapy for the treatment of metastatic and non-metastatic cancer (93-95). Studies have 
suggested that a lack of efficacy was mainly due to clearance of antibody and rapid dissociation 
of antibody-CCL2 complex in vivo, leading to rebound of CCL2 levels during the antibody 
treatment (96). The majority of studies have involved interval injections of CCL2 blocking 
reagents (antibody or inhibitor). Thus, this method of delivery could lead to fluctuations of 
inhibitor levels over time, possibly limiting therapeutic efficacy. Furthermore, pre-clinical 
studies utilized murine specific CCL2 antibodies. To date, human specific CCL2 neutralizing 
antibodies in mouse models have not been extensively tested. 
     This study sought to more fully characterize the effects of human specific CCL2 
neutralizing antibodies on breast cancer progression and determine whether effectiveness was 
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related to method of delivery. Nude mice bearing MCF10CA1d breast tumor xenografts were 
implanted with osmotic pumps containing control IgG or anti-CCL2, and analyzed for CCL2 
levels, and tumor progression over 4 weeks.  Despite inhibiting CCL2-induced migration in 
vitro, CCL2 neutralizing antibodies did not significantly affect breast tumor growth, invasion, 
macrophage recruitment or tumor angiogenesis. CCL2 antibodies significantly increased human 
CCL2 levels in circulating blood and tumor interstitial fluid. CCL2 neutralizing antibodies 
reduced CCL2 levels in cultured cells short-term at high concentrations. ELISA analysis of 
CCL2 in cultured fibroblasts and breast cancer cells revealed that the neutralizing antibodies 
sequestered CCL2 in the media, and that CCL2 levels were restored once the antibodies were 
removed. This study demonstrates that continuous delivery of CCL2 antibodies in vivo is 
possible but reveal limitations to use of neutralizing antibodies as a targeting agent for CCL2, 
with important implications for translating targeted therapies to the clinic. 
Materials and Methods 
Cell culture 
 The human breast cancer cell line MCF10CA1d (CA1d) (63,64) was kindly provided by 
the laboratory of Dr. Fred Miller (University of Michigan).  Human cancer associated fibroblasts 
(hCAF-2300) were isolated from an invasive ductal carcinoma tissues, and characterized 
previously (69,97). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM) 
containing 10% fetal bovine serum (FBS), 2mM L-glutamate and 1% penicillin-streptomycin. 
Human monocyte cell line THP-1 monocytes were kindly provided by Dr. Katherine Fields 
(University of Kansas Medical Center), and were cultured in Roswell Park Memorial Institute 
medium (RPMI) containing 10%FBS and 1% penicillin-streptomycin. DNA genotyping was 
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performed to confirm cell identity. Cells were tested for mycoplasma after thawing using a 
luciferase based mycoplasma assay (Lozona, #LT07-703).  
Transwell migration assay 
 Transwell migration assays were carried out in 24 well plates using Boyden Chambers 
with 5 micron pores (VWR Inc, #10789-236). In the upper chamber, THP-1 cells were seeded at 
100,000 cells per well in 100 ul of RPMI containing 0.1% BSA. At the bottom chamber,  600 ul 
RPMI containing 0.1% bovine serum albumin (BSA) was pipetted into the bottom chamber, in 
the presence or absence of recombinant CCL2 (10, 50 or 100 ng/ml), anti-CCL2 (0.1, 1 or 10 
ug/ml) or IgG isotype control.  Cells were incubated at 37oC for up to 5 hours. Phase contrast 
images were captured at 10x magnification of THP-1 cells migrated to the lower chamber using 
an EVOS FL auto imaging system, with 28 stitched fields per well. The total number of cells for 
each well was quantified using Image J software. 
Animal care and Orthotopic transplantation  
 Athymic nu/nu female nude mice (5-6 weeks old) were obtained from Charles River and 
maintained at the University of Kansas Medical Center animal facilities, under Institutional 
Animal Care and Use Committee and Association for Assessment and Accreditation of 
Laboratory Animal Care International approved guidelines. Breast cancer cells and cancer 
associated fibroblasts were co-grafted into the mammary glands of mice as previously described 
(69). Briefly, 100,000 MCF10CA1d cells and 250,000 hCAF-2300 cells were co-embedded into 
50 ul of rat tail collagen I (Corning Inc, #354236) and cultured overnight at 37oC. The mice were 
anesthetized with 2% isoflurane. A “Y” shape incision was made 1 cm from the base of the tail 
and the skin flaps were folded back to expose the inguinal mammary glands. One plug was 
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inserted into each of the of the #4-5 and #9-10 inguinal mammary fat pads. The wounds were 
closed with wound clips and mice were rehydrated with 0.9% NaCl.  Mice were monitored daily 
for 7 to 10 days until wound clips were removed. Mice were then monitored twice weekly over 
for the next 3 weeks until tumors reached 1.5 cm in size, the maximum tumor size allowable. 
Mice were sacrificed 4 weeks (28 days) post-transplantation. 
Osmotic pump implantation in mice 
 Osmotic pumps were purchased from ALZET (Model 2004), with a manufacture pump 
rate of 0.23 ul per hour over 4 weeks. Osmotic pumps were filled with 1 mg/ml monoclonal 
mouse anti-human CCL2 antibody (R&D system, MAB279) or mouse IgG1 isotype control 
antibody (R&D system, MAB002) according to manufacturer’s instructions. The filled pumps 
were equilibrated for 48 hours by incubation in 0.9% saline at 37oC.  On the day of implantation, 
mice were anesthetized with 2% isoflurane. A 1 cm incision was made in the right dorsum and 
one pump containing IgG or anti-CCL2 was inserted in each mouse (n=5 per group). Pumps 
were implanted immediately after orthotopic transplantation of tumor cells. The wound was 
closed by wound clips. Wound clips were removed 7-10 days after surgery. 
Pump rate analysis 
 Osmotic pump activity was characterized according to manufacturer protocol. Briefly, the 
pump was filled with 0.1% w/v trypan blue (Sigma), placed in 15ml 0.9% saline solution in 50 
ml canonical tube and incubated at 37oC. At day: 2, 3, 4, 7,10, 14, 21 and 28, the trypan blue in 
the saline solution was measured at OD590 (98).  After each measurement, the pump was 




 Mice were anesthetized using 2% isoflurane. Using a 25 gauge needle, blood samples (50 
ul/mouse/time point) were collected on the day before surgery (Day 0), week 2 and week 4 post-
transplantation through the submandibular vein.  To prepare blood samples for ELISA, 0.5 M 
Ethylenediaminetetraacetic acid were added to blood samples at 10% of total volume. Blood 
samples were centrifuged at 2000xg for 15 minutes at 4oC, and the supernatant containing 
plasma proteins were collected for analysis.  
Preparation of tumor tissues for interstitial fluid analysis 
 Interstitial fluid was collected from tumor tissues using a procedures previously described 
(99). 40-100 mg samples from primary tumor tissues were weighed, and homogenized with a 
pellet pestle in PBS added at a ratio of 3 ul: 1 mg. The supernatant was collected after two 
rounds of centrifugation at 16,000g for 15 minutes at 4oC.  
Enzyme-linked immunosorbent assay (ELISA) of CCL2 antibody levels 
 To prepare plates for ELISA analysis of CCL2 antibodies, 96 well high-protein binding 
plates were incubated with 100 ul/well with 10 ng/ml recombinant human CCL2 (Peprotech, 
#300-04) diluted in PBS overnight. Plates were washed with PBS/0.05% Tween-20 and then 
wells were blocked with PBS containing 10% BSA for 2 hours. Wells were coated with CCL2 
antibodies as standards, which were diluted to final concentrations of: 10 ug/ml, 1 ug/ml, 500 
ng/ml, 100 ng/ml, 10 ng/ml and 1 ng/ml in PBS/2% BSA.  As a negative control, wells were 
coated with IgG1 isotype control at a final concentration of 1 ug/ml. Wells were incubated with 
100 ul of plasma or tumor interstitial fluid samples diluted 1:100 in PBS/2% BSA.  Samples 
were incubated for 2 hours at room temperature, washed with PBS/0.05% Tween-20 and then 
incubated with 0.5 ug/ml biotinylated goat anti-mouse detection antibody (Vector Laboratories, 
82 
 
#VA-9200) for 2 hours.  Samples were then incubated with streptavidin conjugated to horse 
radish peroxidase (Vector Laboratories, #900-K31) for 30 minutes. Reactions were catalyzed 
with TMB substrate (Thermo Scientific, #34028), stopped with 2N HCl, and read at OD450. 
CCL2 antibody levels were normalized to wells incubated with 2% BSA non-specific binding 
control.  
CCL2 ELISA  
 Plasma samples were diluted 1:4 in phosphate buffered saline (PBS) containing 
0.1%BSA and 0.05% tween-20.  Tumor interstitial fluid samples were diluted 1:20. Samples 
were assayed using mouse CCL2 ELISA kit (Peprotech, #900-K59) or human CCL2 ELISA kit 
(Peprotech, # 900-K31) according to manufacturer protocol.  
     To generate conditioned medium, MCF10CA1d or hCAF-2300 cells were seeded at 
10,000 cells per well, in triplicate in a 24 well plate. Cells were then incubated with 500 ul of 
DMEM/10% FBS in the presence or absence of control IgG or CCL2 antibody (1 or 10 ug/ml) 
for 24 hours. The medium containing IgG or anti-CCL2 were collected and assayed for CCL2 
levels by ELISA (Peprotech, #900-K31). To analyze for CCL2 levels post-antibody treatment, 
the cells were washed once with PBS and re-incubated in serum free medium without IgG or 
antibody treatment for an additional 24 hours. The samples were collected and assayed for CCL2 
levels by ELISA. 
Tissue embedding and histology 
 Tumor samples were fixed in 10% neutral buffed formalin overnight, and then 
dehydrated in a series of: 70%, 90% and 100% ethanol for 30 minutes each. Tissues were further 
dehydrated in isopropanol for 1 hour, 50:50 isopropanol: wax at 60oC for 1 hour, and in wax 
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overnight at 60oC. Tissues were mounted on cassettes and sectioned into 5 micron thin slices 
onto glass slides.   For H&E stain, slides were dewaxed in two changes of xylenes at 5 minutes 
each and rehydrated in a series of ethanol (100%, 90%, 70%, 50%) at 3 minutes each. Slides 
were stained with Mayer’s hematoxylin for 2 minutes and eosin for 1.5 minutes, dehydrated and 
then mounted with Cytoseal under glass coverslips.  
Co-Immunofluorescent staining and immunohistochemistry 
 For co-immunofluorescent staining, dewaxed slides were subject to antigen retrieval 
using 10 mM sodium citrate buffer pH 6.0 for 20 minutes in pressure cooker under low pressure 
setting for antigen retrieval. Samples were blocked for endogenous mouse IgG using the M.O.M 
kit (Vector Lab., #BMK-2202), and then incubated with mouse anti-cytokeratin 5 (CK5) at a 
1:50 dilution (Thermo Fisher Scientific, #MA5-12596 ) and with rat anti-F4/80 (Abcam, 
#ab6640) at a 1:100 dilution in PBS 3%FBS.  After overnight staining at 4oC, slides were 
washed three times in PBS containing 0.05% Tween-20, incubated with Alexa Fluor 568 goat 
anti-rat dilution (Invitrogen, #A11077) and Alexa Fluor 488 goat anti-mouse at a 1:100 dilution 
(Invitrogen, #A11001) for 2 hours. Slides were counter-stained with 4',6-diamidino-2-
phenylindole (DAPI) at a 1:500 dilution, and then mounted in PBS containing 50% glycerol. 
Eight high power images for each slide were acquired using the FL Auto EVOS imaging system 
at 20x magnification. For image analysis, F4/80 positive cells per image were quantified using 
Image J particles analysis with threshold set above background. For compartmental analysis, the 
stroma at the tumor periphery was defined as the area bordering the tumor that was negative for 
CK5 staining. The tumor core was defined as areas positive for CK5 expression. F4/80 cells in 
each of the compartments were quantified and normalized to area size.  
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     For immunohistochemistry staining, dewaxed slides were subject to antigen retrieval in 
treated in sodium citrate buffer, and blocked for endogenous peroxidase activity in deionized 
water (80%): methanol (10%): hydrogen peroxide (10%) for 10 minutes.  After blocking for 1 
hour in PBS/5% FBS, slides were incubated with rabbit anti-von Willebrand Factor 8 (vWF8) at 
a 1:100 dilution (Chemicon International, #AB7356) overnight. Slides were washed in PBS 3 
times for 10 minutes each, incubated with biotinylated anti-rabbit secondary antibody at a 1:500 
dilution and then incubated with peroxidase conjugated to streptavidin (Vector Lab., #PK-6100) 
for 30 minutes. Protein expression was detected using 3,3'-diaminobenzidine (DAB) substrate 
(Vector Lab., #SK-4100) . Slides were counter-stained with Mayer’s hematoxylin for 2 minutes, 
dehydrated and mounted with Cytoseal (Thermo Fisher, #348976). Eight images per samples 
were acquired under 10x magnification using the FL Auto EVOS imaging system.  Expression 
was quantified by Image J software using procedures previously described (61). 
Lung whole mount staining  
 Lung metastasis was analyzed by whole mount staining as described previously (38). 
Briefly, lung tissues were fixed in neutral buffered formalin overnight at 4oC, and dehydrated on 
70%, 95% and 100% ethanol for 1 hour each. Lung tissues were cleared in xylene overnight, 
rehydrated through a series of 100%, 95% and 70% ethanol, and counter-stained with 
hematoxylin for 5 minutes. Tissues were de-stained in 1% HCl and incubated with tap water for 
10 to 20 minutes. Micro-metastases were counted using a Motic AE31 inverted microscope at 




 Statistical analysis was performed using Graphpad software. Two tailed Student T test 
was used for two group comparisons. One Way ANOVA with Bonferroni post-hoc comparison 
was used for multiple group comparisons. Statistical significance was determined by p<0.05. 
*p<0.05, **p<0.01, ***p<0.001, ns=not significant (p>0.05). 
Results 
Neutralizing antibodies specifically block cell migration induced by human recombinant 
CCL2 
 Multiple studies have utilized murine CCL2 neutralizing antibodies to demonstrate that 
targeting CCL2 activity inhibits mammary tumor progression (36,38,91,92).  Murine CCL2 
exhibits a 70% protein homology to human CCL2, indicating high degree of conservation (27).  
The difference in sequence homology could affect receptor binding and activity. While the goal 
is to develop clinically active neutralizing antibodies for patients, i.e. antibodies that target 
human tissues, there have been few studies characterizing the effectiveness of human specific 
CCL2 neutralizing antibodies on cancer progression in mouse models, relative to endogenous 
and exogenous CCL2 levels. To address this issue, we obtained human specific CCL2 
neutralizing antibodies from a commercial source (R&D systems) and first analyzed the 
specificity of neutralization of murine and human CCL2. THP-1 human monocytes were 
cultured in vitro, stimulated with increasing dosages of murine or human CCL2 and analyzed for 
transwell migration.  Both murine and human CCL2 were found to increase migration of THP-1 
cells at 10 ng/ml, indicating cross reactivity between mouse CCL2 and human CCR receptors. 
Chemotaxis decreased at 50 and 100 ng/ml, possibly reflecting desensitization of chemokine 
receptors at excess ligand concentrations. Human CCL2 induced migration with a wider range of 




Figure 21. Neutralizing antibodies inhibit THP1 cell migration induced by recombinant 
human CCL2 protein. A. THP1 cells were stimulated with increasing concentrations of human 
(hCCL2) or mouse (mCCL2) recombinant CCL2 protein and analyzed for transwell migration 
after 2 hours. Representative images of cells migrated into lower chamber are shown. B. THP1 
cells were stimulated with 10 ng/ml hCCL2 or mCCL2 in the presence or absence of increasing 
doses of CCL2 neutralizing antibodies or control IgG, and analyzed for transwell migration. 
Representative images of cells treated with CCL2 and 1 ug/ml control IgG or CCL2 neutralizing 
antibodies. Statistical analysis was performed using One Way ANOVA test, with Bonferroni post-
hoc comparison. Statistical significance was determined by *p<0.05, ***p<0.01, and n.s=not 




cells to human CCL2, compared to murine CCL2. Treatment of THP-1 cells with 1 ug/ml CCL2 
neutralizing antibodies inhibited migration induced by human CCL2 but not mouse CCL2 
(Figure 21B), indicating that CCL2 neutralizing antibodies specifically block human CCL2.   
CCL2 neutralizing antibodies delivered by osmotic pumps penetrate primary MCF10CA1d 
breast tumor xenografts 
 As the majority of studies involving CCL2 antibody delivery in vivo involved interval 
injections, we asked whether continuous delivery of CCL2 antibodies would increase therapeutic 
effectiveness. Osmotic pump delivery of CCL2 antibodies could stabilize drug levels and 
avoiding dosage fluctuations caused by interval drug injections (100-102). We obtained mini-
osmotic pumps (Alzet) capable of continuous drug delivery for 4 weeks in tumor bearing mice. 
To characterize their long-term function, osmotic pumps were filled with trypan blue dye, placed 
in 50 ml conical tube containing sterile saline solution in cell culture incubator (Figure 22A). 
Pump activity was monitored over 4 weeks through sampling of saline and absorbance 
Figure 22. Characterization of osmotic pump rate in vitro 
Figure 21. Neutralizing antibodies inhibit THP1 cell migration induced by recombinant human CCL2 protein 
Figure 22. Characterization of osmotic pump rate in vitro. A. Diagram of how osmotic pump 
activity was tested in vitro using trypan blue dye. Osmotic pumps were filled with trypan blue 
dye and placed in 50 ml conical tubes containing saline solution. Activity was determined by 
measuring the optical density (OD590) of trypan blue in saline over 4 weeks. B. The levels of 
trypan blue effluxed into saline solution was plotted against OD590. C. Volume of trypan blue 





measurement of trypan blue (Figure 22B). After 3 days of incubation, the pump rate was found 
to be stable over 4 weeks, with an average rate of 5.9 ul per day (Figure 22C). This rate was 
close to the expected pump rate of 5.52 ul per day. 
     In previous studies, we had shown that breast stromal fibroblasts and cancer cells 
expressed high levels of CCL2, and CCL2 expression in basal-like breast cancers correlated with 
poor patient prognosis in basal-like breast cancers (38,69). Therefore, we analyzed the 
Figure 23. Osmotic pump delivery of CCL2 neutralizing antibodies in the MCF10CA1d breast tumor xenograft 
model 
Figure 23. Osmotic pump delivery of CCL2 neutralizing antibodies in the MCF10CA1d 
breast tumor xenograft model. A. Diagram of pump implantation. Mice orthotopically 
transplanted with fibroblasts and MCF10CA1d breast cancer cells were implanted with 
osmotic pumps containing CCL2 neutralizing antibodies or isotype control IgG1 for 4 weeks 
(N=5/group). B. The volume of fluid pumped out was determined by subtracting the residual 
volume from initial volume after 4 weeks in vivo implantation. Dotted line indicates the 
expected volume pumped out (155 ul). C. Measurement CCL2 antibody concentration in 
blood by ELISA. D. ELISA analysis of tumor interstitial CCL2 antibody concentration in 
harvested tumor samples after 4 weeks of implantation. Statistical analysis was performed 
using Two Tailed Student T test. Statistical significance was determined by p<0.05. n.s=not 




effectiveness of osmotic pump delivery of CCL2 neutralizing antibodies on tumor growth and 
progression using the MCF10CA1d model of basal-like breast cancer (63,64). MCF10CA1d 
breast cancer cells were co-grafted with human breast cancer associated fibroblasts in the 
mammary glands of nude mice. Osmotic pumps with an expected delivery of rate of 0.3 
mg/kg/day will filled with 1 mg/ml control IgG or anti-CCL2, and then implanted 
subcutaneously immediately after cellular transplantation (Figure 23A).  
     Mice were treated for 4 weeks until the control tumor reached 1.5 cm in size, the 
maximum allowable tumor size. We determined the efficiency of osmotic pump activity by 
measuring the volume of IgG and anti-CCL2 delivered. The residual volumes in the pumps were 
subtracted from the starting volume of 234±2 ul. In the anti-CCL2 treated group, osmotic pumps 
delivered 186±13 ul compared to 180±20 ul of control IgG delivered, indicating consistent pump 
activity between groups (Figure 23B). To determine the levels of anti-CCL2 in blood circulation, 
anti-CCL2 levels were measured by ELISA from blood sampled at day 0, the day before surgery, 
Figure 24. Location of breast tumor xenografts is not a factor in CCL2 antibody uptake or 
CCL2 levels. MCF10CA1D breast tumors grafted into the #4-5 and #9-10 inguinal mammary 
glands.  Tumor tissues from anti-CCL2 treated animals were analyzed for levels of A. CCL2 
antibodies and B. human CCL2 by ELISA. Statistical analysis was performed using Two Tailed 
Student T test. Statistical significance was determined by p<0.05. n.s=not significant. 
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2 weeks and 4 weeks post-surgery.  Anti-CCL2 levels were undetectable before implantation, but 
21 ug/ml were detected at week 2, and 18 ug/ml at week 4, indicating systemic delivery over 
time (Figure 23C).  To determine whether anti-CCL2 penetrated the primary tumor, antibody 
levels in the tumor interstitial fluid were measured by ELISA.  Approximately 1.1 ug/ml of anti-
CCL2 were detected within the tumor, relative to control IgG treated mice (Figure 23D).  
Placement of the tumor in either the #4-5 or #9-10 inguinal mammary gland did not affect 
antibody penetration or CCL2 levels (Figure 24). In summary, these data indicate osmotic pump 
delivery of CCL2 neutralizing antibodies lead to stable antibody levels and penetrate tumor 
tissues.  
CCL2 neutralizing antibodies do not significantly affect progression of MCF10CA1d breast 
tumor xenografts 
 To determine the effect of anti-CCL2 on tumor growth and invasion, mice were measured 
for tumor growth on a weekly basis for up to 4 weeks. Compared to control IgG treated mice, 
anti-CCL2 treated tumors did not show significant changes in tumor growth over time or tumor 
mass 4 weeks post-treatment (Figure 25A-B). By H&E stain, primary tumors from IgG and anti-
CCL2 treated mice appeared to be high grade tumors, exhibiting extensive necrosis and tumor 
invasion into the fat pad (Figure 25C). By whole mount staining and H&E stain of lung tissues, 
there were no significant differences in lung metastasis between IgG and anti-CCL2 treated mice 
(Figure 25D-E). We examined for possible changes in tumor angiogenesis and macrophage 
recruitment by immunostaining of primary tumors. Sections were co-immunofluorescent stained 
for antibodies to F4/80, a macrophage marker, with human specific CK5 to distinguish 
MCF10CA1d breast cancer cells. Macrophages were primarily detected at the edge of the tumor, 




Figure 25. CCL2 neutralizing antibodies do not significantly affect progression of 
MCF10A1D breast tumor xenografts. IgG control or CCL2 antibody treated mice were 
analyzed for: A. tumor growth over time, B. tumor mass at 28 days, C. malignancy as assessed 
by H&E stain of primary tumor tissues and D. lung metastasis, which was assessed by lung 
whole mount staining. E. Lung metastasis was validated by H&E stain.  Representative 
metastatic lesion is circled.  Statistical analysis was performed using Two Tailed Student T test. 
Statistical significance was determined by p<0.05. n.s=not significant. Mean+SEM are shown. 
Scale bar= 200 microns. 





Figure 26. Delivery of CCL2 neutralizing antibodies do not significantly affect 
macrophage infiltration or tumor angiogenesis. A. Primary tumor tissues were co-
immunofluorescent stained for Cytokeratin 5 (CK5, green) and F4/80 (red). 
Secondary antibody controls overlayed with DAPI are shown. B. Primary tumor 
tissues were immunostained for von Willebrand Factor 8 (vWF8). Magnified insert 
shows positive staining. Staining was quantified by Image J. Statistical analysis was 
performed using Two Tailed Student T test. Statistical significance was determined by 





Figure 27. Quantification of F4/80 macrophage infiltration in MCF10CA1D 
primary tumor tissues. A. Primary breast tumor xenografts were co-immunofluorescent 
stained for Cytokeratin 5 (CK5) and F4/80. F4/80+ cells were localized at the invasive 
edge (IE) and within the tumor core (TC). Representative image is shown. Scale bar=200 
microns. B.  F4/80 cells were quantified at the invasive edge and tumor core per mm3 
using Image J software. Statistical analysis was performed using Two Tailed Student T 
test. Statistical significance was determined by p<0.05. n.s=not significant. Mean+SEM 
are shown. 
 
Figure 27. Quantification of F4/80 macrophage infiltration in MCF10CA1D primary tumor tissues 
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There were no differences in total levels of macrophages regardless of localization, between IgG 
and anti-CCL2 treated mice (Figure 26A and 27).  By vWF8 staining, there were no significant 
differences in tumor angiogenesis between IgG and anti-CCL2 treated mice (Figure 26B).  
CCL2 neutralizing antibodies increase CCL2 levels in mice bearing MCF10CA1d breast 
tumor xenografts  
 Given the lack of therapeutic efficacy with neutralizing antibodies, we examined for 
CCL2 expression levels in tumor bearing mice.  CCL2 levels were measured from blood samples 
and tumor interstitial fluid by ELISA.  Mice treated with CCL2 antibodies showed significantly 
higher levels of human CCL2 in blood samples with a mean concentration of 603 ng/ml, 
compared to 346 ng/ml in IgG treated mice (Figure 28A). Anti-CCL2 treatment also increased 
expression of human CCL2 in the tumor interstitial fluid with a mean concentration of 3.5 ng/ml 
compared to 1.2 ng/ml in the control IgG group (Figure 28B).  Furthermore, blood samples from 
Figure 28. Delivery of CCL2 neutralizing antibodies to tumor bearing mice increases 
the levels of human CCL2 in blood and in primary tumor tissues. Tumor bearing mice 
were treated with control IgG or CCL2 neutralizing antibodies. 4 weeks post-
transplantation, ELISAs were performed to measure the levels of: A. human CCL2 in 
blood, B human CCL2 in tumor interstitial fluid, and C. murine CCL2 in blood. Statistical 
analysis was performed using Two Tailed Student T test. Statistical significance was 
determined by p<0.05. **p<0.01, ***p<0.001, n.s=not significant. 
 
Figure 28. Delivery of CCL2 neutralizing antibodies to tumor bearing mice increases the levels of human CCL2 
in blood and in primary tumor tissues 
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anti-CCL2 treated mice showed a modest but not statistically significant increase in murine 
CCL2 expression (Figure 28C).  
     We addressed the possibility that anti-CCL2 treatment led to compensatory upregulation 
of CCL2 in breast cancer cells and fibroblasts, thereby increasing the levels found in circulation 
and in tumor tissues. MCF10CA1d breast cancer cells and fibroblasts were cultured in the 
presence or absence of anti-CCL2 or control IgG and measured for CCL2 secretion by ELISA.  
CCL2 expression in fibroblasts was twice as high compared to MCA10CA1D cancer cells. 
Increasing the concentration of anti-CCL2 to10 ug/ml reduced the levels of CCL2 in fibroblasts 
Figure 29. CCL2 levels in cultured cells are dependent on the presence of neutralizing 
antibodies. Cultured MCF10CA1d breast cancer cells or hCAF-2300 fibroblasts were 
treated with control IgG or CCL2 neutralizing antibodies for 24 hours. A. Medium was 
analyzed for CCL2 expression by ELISA. B. Cells were washed to remove antibodies and 
incubated in serum free condition medium for an additional 24 hours. CCL2 levels in 
conditioned medium were analyzed by ELISA.  Statistical analysis was performed using 
One Way ANOVA test with Bonferroni post-hoc comparison. Statistical significance was 
determined by p<0.05.*p<0.05, n.s=not significant. 
Figure 29. CCL2 levels in cultured cells are dependent on the presence of neutralizing antibodies 
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from 2300 pg/ml to 1000 pg/ml, and resulted in a small but not statistically significant decrease 
in CCL2 levels in breast cancer cells to 1000 pg/ml (Figure 29A). The presence of neutralizing 
antibodies inhibited detection of recombinant CCL2, indicating that the ELISAs detected free 
CCL2 secreted from cells, but not CCL2 bound to neutralizing antibodies. To further determine 
how the presence of anti-CCL2 affected CCL2 levels in cultured cells, the antibody containing 
medium was removed, and cells were incubated in fresh medium for 24 hours to generate 
conditioned medium. When the conditioned medium was examined for CCL2  by ELISA, there 
were no significant differences in CCL2 levels in fibroblasts or breast cancer cells compared to 
IgG treatment (Figure 29B).  In summary, these data indicate that neutralizing antibodies are 
capable of binding and sequestering free CCL2, but a continuous presence of CCL2 antibodies is 
required to maintain this sequestration.  
Discussion 
 CCL2 is a therapeutic target of interest for the treatment of cancer, and the effectiveness 
of CCL2 targeting alone, or in combination with other agents, is currently being determined in 
multiple clinical trials (93-95).  However, human specific CCL2 antibodies have not been well 
characterized in pre-clinical studies. Furthermore, the primary method for targeting CCL2 has 
involved bolus injections of neutralizing antibodies. In these studies, we tested whether 
continuous delivery of human specific CCL2 neutralizing antibodies in animals bearing breast 
tumor xenografts, would be an effective therapeutic strategy. Our studies showed that stable 
delivery of CCL2 neutralizing antibodies over 4 weeks results in little therapeutic efficacy and 
increased CCL2 levels over time. 
     Previous studies have demonstrated that drugs delivered via osmotic pumps enhance 
therapeutic efficacy compared to bolus injections (101,103-105). For example, osmotic pump 
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delivery of carboplatin to mouse models of ovarian cancer inhibited tumor growth more 
effectively than intraperitoneal injection and resulted in fewer toxic side effects (105). In another 
study, osmotic pump delivery of Interleukin13 drug conjugates significantly slowed tumor 
growth and increased survival in animals with pancreatic cancer (104).  These therapeutic effects 
are in part due to stable drug delivery modulated by osmotic pumps  (101). In previous studies, 
we found that interval injections of CCL2 antibodies in mice resulted in a 1/3 decline of antibody 
levels within 24 hours (38).  Here, we found that osmotic pump delivery of CCL2 neutralizing 
antibodies resulted in stable levels of antibody approximately 18 to 20 ug/ml in circulation over 
several weeks, while 10 ug/ml was shown to be inhibitory in vitro. However, osmotic pump 
delivery of CCL2 neutralizing antibodies did not significantly affect primary tumor growth or 
invasiveness. One possible factor limiting the effectiveness of the neutralizing antibody is tissue 
penetration. Approximately 1.1 ug/ml of antibodies were detected in tumor tissues, compared to 
18-20 ug/ml in blood circulation. These data indicate that significantly lower levels of antibodies 
penetrated tumor tissues.  Difficulties in drug penetration have been reported in animal models 
and in patients, and have been attributed to a number of factors including: leaky vasculature that 
does not extend into the tumor, tumor interstitial pressure, and a basement membrane that 
provides a barrier to drug entry (106).  It would be of interest in the future to further investigate 
the mechanisms preventing antibody uptake, in order to enhance therapeutic efficacy.  
     In order to test the effectiveness of human specific CCL2 therapeutic antibodies in pre-
clinical models involving human and mouse cells, it was necessary to determine how the 
antibody would cross react with other species.  Previous studies have shown that murine specific 
CCL2 antibodies inhibited tumor growth and metastasis transplanted with murine mammary or 
prostate carcinoma cells (38,107).  One study showed that murine specific CCL2 neutralizing 
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antibodies inhibited the growth of MDA-MB-231 breast tumor xenografts and macrophage 
recruitment in mice (35).  The limited effectiveness of human specific CCL2 antibodies observed 
in our studies could be due in part to binding specificity. Human and mouse CCL2 share a 70% 
homology in amino acids (27) enabling human cells to respond to recombinant protein from both 
species. While both murine and human CCL2 stimulated human cells in vitro, the neutralizing 
antibodies inhibited human but not murine CCL2 induced cell migration.  Antibody treatment of 
tumor bearing mice increased the levels of human CCL2, and also murine CCL2 in circulation, 
although the increase in murine CCL2 was not statistically significant. CCL2 is expressed by a 
variety of murine cell types found within the primary breast tumor, including endothelial cells 
and bone marrow derived cells (27). It is possible that the combined increase in human and 
murine CCL2 abrogated the effects of CCL2 antibody neutralization.  
     The CCL2 antibody concentrations detected in blood circulation and in tumor tissues 
were associated with increased human CCL2 levels and slight increase in murine CCL2 levels, 
indicating a physiological effect of CCL2 antibody delivery.  These phenotypes are consistent 
with previous studies characterizing the effects of antibody targeting of ligands. Delivery of the 
CCL2 neutralizing antibody, CNTO0800 resulted in elevated CCL2 levels in patients during 
clinical trials (94,95). Mathematical modeling studies indicated that antibody binding prevented 
clearance of CCL2, and that a rapid disassociation of antibodies from the ligand contributed to 
the increased levels of free CCL2 (96). In our studies we found a 2-3 fold increase in CCL2 
levels with antibody treatment in animals. Treatment of cultured cells with CCL2 antibodies 
reduced the levels of free CCL2 in fibroblasts and slightly decreased levels in breast cancer cells. 
However, 1000 pg/ml of CCL2 was still detectable even with 10 ug/ml of antibody present. This 
may potentially be due to the equilibrium between bound and unbound of CCL2. After removal 
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of antibodies, we found the CCL2 expression levels in cultured cells were similar to control 
treatment, ruling out of compensatory CCL2 production. Thus, the increased level of CCL2 
observed in vivo could be potentially due to the enhanced stability of CCL2 by antibody binding, 
and a constant equilibrium between binding and dissociation of CCL2-antibody complexes.  It 
would be of interest in the future to conduct studies on the pharmacokinetics of CCL2 antibodies 
in animal models of breast cancer.    
     In these studies, we delivered CCL2 neutralizing antibodies at a dosage of approximately 
0.3 mg/kg/day. This dosage was based on previous studies reporting effectiveness of CCL2 
neutralizing antibodies when delivered at dosages ranging from 0.4 mg/kg/day to 2.9 mg/kg/day 
(36,38,87). The slightly lower dosage was due to limitations in pump rate from an osmotic pump 
capable of drug delivery over 4 weeks. It is possible that a higher concentration of CCL2 
antibodies might induce an anti-cancer effect, or might further elevate CCL2 levels, contributing 
to a rebound effect that promotes tumor progression.  These studies would require a higher pump 
rate with shorter pump time, requiring more frequent pump replacement in the MCF10CA1d 
tumor model, increasing physical stress to the animals. From a clinical perspective, this would 
require long-term continuous delivery of high dosages of anti-CCL2 to prevent a possible 
rebound effect caused by decreased CCL2 antibody levels.    
Conclusions 
 In summary, our studies report limitations in the use of human specific CCL2 
neutralizing antibodies for the treatment of breast cancer in mouse models.   Previous studies 
have shown that knockdown of CCL2 in breast tumor xenografts effectively inhibited tumor 
growth and metastasis, and significantly reduced CCL2 levels (54,69). These studies suggest that 
CCL2 remains viable therapeutic target in anti-cancer treatment. Strategies to inhibit CCL2 
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expression, rather than CCL2 activity only, may be a more effective approach to target CCL2.  
Alternatively, CCR2 inhibitors, which are in the pre-clinical pipeline (90) may overcome 
limitations caused by CCL2 targeting. Furthermore, the development of more physiologically 













 In this thesis study, we found that the chemokine CCL2/CCR2 signaling played an 
important role in mediating cancer associated fibroblasts and cancer cells interaction in basal-like 
breast cancer progression (Figure 30). We started by analysis the expression of CCL2 and its 
receptor CCR2 in breast cancer samples. We found that the chemokine CCL2 was highly 
expressed in invasive ductal carcinoma, and positively correlated with expression of fibroblasts 
maker Fsp1. High stromal CCL2 expression associated with reduced recurrence free survival in 
basal-like subtype. Further data mining in the breast cancer TCGA and METABRIC datasets 
revealed that CCL2 and CCR2 expressed highest in the basal-like subtypes, and were positively 
correlated. Those studies indicate the CCL2/CCR2 signaling potentially function as an important 
signaling pathway in the progression of basal-like breast cancer. 
 We confirmed that CAFs isolated from primary human and mouse breast cancer samples 
generally expressed high level of CCL2. CAFs promoted basal-like breast cancer cell line 
MCF10A-CA1D xenograft growth in the fibroblast-cancer cell co-graft model. Depletion of 
CCL2 expression from CAFs significantly reduced their cancer promotion ability. In contrast, 
CCL2 derived from cancer cells, which was expressed in much lower level, did not significantly 
contribute. Those studies indicate that CAFs are a major cellular source of CCL2 in the breast 
cancer model. 
 To determine the mechanism of CCL2 in tumor promotion, we found that fibroblasts 
conditional medium or recombinant CCL2 promoted breast cancer cell growth in vitro. Mutation 
of the CCR2 receptor in CA1D cancer cell significantly reduced cancer cells growth in vitro and 
in vivo in response to CCL2 stimulation. We further identified that the PKC and SRC pathways 
functioned downstream of CCL2/CCR2 signaling and contributed to CCL2 mediated growth 
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promotion. Those results provide a functional evidence of the importance of direct CCL2 
signaling to basal-like breast cancer cells.  
 We aimed to test the therapeutic effect of blocking CCL2 in breast cancer mouse model 
through continuous delivery of CCL2 neutralizing antibody using the osmotic pump. Despite the 
steady delivery of the antibody, CCL2 blocking did not 
significantly affect tumor progression. Examination of 
CCL2 level in blood and tumor site revealed that CCL2 
blocking significantly induced higher free CCL2 level, 
which may contribute to lack of efficacy. This study pointed 
out a potential unexpected effect in targeting CCL2 
signaling by blocking antibody, consistent with earlier 
observations in human patients (94,95). This failed pre-
clinical trial does not devaluate the CCl2 signaling as 
potential therapeutic targets, rather it points out optimized 
targeting strategies are needed. Alternative CCL2 signaling 
targeting approaches, such as by CCR2 inhibitor, may 
provide better therapeutic efficacy. 
     In summary, our studies reveal that cancer 
associated fibroblasts are an important cellular source of CCL2 in breast cancer. The 
CCL2/CCR2 signaling promotes the basal-like breast cancer promotion, through directly 
signaling to the CCR2 receptor in cancer cells (Figure 30). Thus, the CCL2/CCR2 signaling can 
serve as potential therapeutic targets in basal-like breast cancer. 
Figure 30. Overall conclusions and 
models 
Figure 30. Overall 
conclusions and models. 
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Significance and Innovation 
 Basal-like breast cancer represents about 12% of total invasive breast cancer, with 
estimated 30, 325 cases in 2017 in U.S. women (1). Basal-like breast cancer is the most 
aggressive breast cancer subtype with the worst patient outcome (1). This is mainly due to lack 
of targeted therapies, compared to other breast cancer subtypes. Conventional prognostic 
indicators such as grade and stage do not accurately predict patient prognosis for basal-like 
breast cancer subtypes (50,51), indicating the need to identify prognostic factors unique to each 
subtype. In these studies, we have identified that stromal CCL2 is an independent prognosis 
factor. In both univariable and multivariable analysis, stromal CCL2 significantly associated 
with recurrence free survival, with high hazard ratio. In comparison, other traditional prognosis 
factors, including TNM stage, grade and treatment options, did not significantly associated with 
patient outcome (Table 8). Thus, we have identified an additional critical prognosis factor that 
can be potentially used for basal-like breast cancer subtype. In addition, we report in these 
studies that the chemokine CCL2 and its receptor CCR2 express highest in basal-like breast 
cancer, and function importantly in promoting basal-like breast cancer progression. Thus the 
CCl2/CCR2 signaling can potentially serve as new therapeutic targets in basal-like breast cancer. 
 The stromal environment has emerged as a critical player in tumor progression (14). 
CAFs are the most abundant stroma cells present in cancers. Previous studies have suggested 
CAFs play important roles in tumor growth and metastasis (15). Thus, targeting CAFs has been 
proposed as promising alternative therapeutic strategy (108). However, directly targeting CAFs 
is difficult, due to lack of CAFs unique molecular markers (15). Thus, targeting cancer 
promoting factors derived from fibroblasts may serve as alternative approaches. In these studies, 
we report that CAFs are a major cellular source of CCL2, and CCL2 plays an important role in 
105 
 
breast cancer progression. Our studies provide a new molecular mechanism of cancer associated 
fibroblasts in cancer promotion through CCL2, which can potentially serve as a therapeutic 
target.   
 Chemokine CCL2 expression has been shown to elevate in various cancer types, 
including breast cancer and prostate cancer (32). The mechanistic role of CCL2, however, has 
been most studied in the focus of monocyte/macrophage recruitment in cancer (36). It is largely 
unknown whether CCL2 can directly signal into breast cancer cells. In this study, we have 
identified a novel mechanism of CCL2 function through directly signaling to cancer cells 
through CCR2. Mutation of CCR2 receptor in cancer cells significantly reduces tumor growth in 
vivo in response to fibroblasts derived CCL2.  Our studies provide the first in vivo evidence on 
the importance of direct CCL2 signaling into breast cancer.  
 Conceptually, our studies address the role of tumor stroma in cancer progression, and 
specifically focus on CCL2/CCR2 signaling mediated fibroblast and breast cancer cell 
interaction. In addition, our studies uncover a novel mechanism of CCL2 function by directly 
signaling to breast cancer cells through CCR2 receptor.  
 In this study, we have generated valuable materials for CCL2 signaling studies. We have 
derived multiple primary breast CAFs cell lines. We have generated multiple CCL2 and CCR2 
mutant or knockdown cell lines. All of those will provide valuable resources for the laboratory 
and the scientific community. We have also used innovative tools to address those questions 
through in vitro and in vivo models, such as the 3-dimensional culture model and co-graft tumor 
model. Taken together, our studies have been carried out using innovative and convincing 




 The CCL2/CCR2 signaling has been continually pursued as therapeutic targets in both 
immune disease and cancer. In earlier clinical trials, CCL2 blocking antibody had been tested in 
primary and metastatic cancers, either used as a single agent or in combination with 
chemotherapy. Unfortunately, in all the trials, CCL2 inhibition by blocking antibody did not 
result in objective responses in cancer patients (93-95). Analysis of CCL2 level in patient blood 
samples revealed that the blocking antibody was not able to suppress CCL2 level overcome time 
(96). More recently, a new clinical trial with CCR2 inhibitor showed promising efficacy. In a 
stage I clinical trial in localized pancreatic cancer, treatment with the combination of CCR2 
inhibitor PF-04136309 and chemotherapy led to 49% objective response (90). In contrast, 
chemotherapy alone treatment did not result in any objective response. Many other ongoing 
clinical trials are designed to combine CCR2 inhibition with checkpoint blockade therapy in 
immunotherapy.   
 Our studies indicate that the CCL2 signaling functions importantly in basal-like breast 
cancer progression. We also uncover a novel mechanism of CCL2 function through directly 
signaling to breast cancer cells. These studies will provide rationale in potentially targeting 
CCL2 signaling in basal-like breast cancer in clinic. In addition, CCL2 inhibition in clinical can 
potentially lead to a dual anti-cancer mechanism--blocking tumor promoting myeloid cells 
recruitment and blocking direct cancer cells signaling (Figure 31). 
 In our pre-clinical trial mouse model, we have attempted to develop an alternative 
approach to overcome the previous failure of CCL2 antibody in clinical trials. We ration that 
continual delivery of CCL2 blocking antibody would lead to steady antibody level and better 
therapeutic efficacy, compared to traditional interval injection used in earlier clinical trials. 
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Figure 31. Clinical application of CCL2/CCR2 
signaling targeting in breast cancer. 
However, our studies result in similar failure in controlling tumor progression in mouse model. 
We have observed an increased free CCL2 level with CCL2 blocking antibody, consistent with 
earlier reports (95). So those studies indicate a potential problem in targeting CCL2 with 
blocking antibody. Alternatively, 
targeting CCL2 signaling with CCR2 
inhibitors may provide better clinical 
efficacy.  
Limitations and future directions 
 While our studies provide 
valuable insights on CCL2 signaling in 
basal-like breast cancer progression, the 
studies are limited by methods and experimental models used. Future studies with additional 
tumor models will provide a further understanding of CCL2 signaling and stromal fibroblast 
functions in breast cancer.   
 First of all, the fibroblast-cancer cell co-graft model provides a useful system to facilitate 
genetic modulation of individual factors in fibroblasts or cancer cells. However, the grafted 
fibroblasts have limited proliferation capacity in vivo, and can be compensated by mouse stromal 
fibroblasts recruited into the tumor. In our experience, the effect of grafted fibroblasts in tumor 
growth promotion was most prominent in the first four weeks. After that, the tumor growth slope 
was similar to CA1D cancer cells grafted alone. Histology analysis revealed that cancer cells 
recruited mouse stromal fibroblasts infiltration/proliferation, which may compensate for the 
function of grafted fibroblasts. This is relevant because mouse Ccl2 derived from mouse 
Figure 31. Clinical application of CCL2/CCR2 signaling 
targeting in breast cancer 
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fibroblasts can also signal to human CCR2 in cancer cells and promote tumor progression. To 
overcome this, a mouse genetic model with conditional knockout CCL2 in fibroblast lineage is a 
more desirable tumor host. This can be potentially achieved by crossing mouse strain with CCL2 
flox allele (109) with Cre recombinase expressed in fibroblasts lineage, such as Fsp1-cre mice 
(22). We expect that conditional knockout of CCL2 in fibroblasts will reduce grafted tumor 
growth more dramatically compared to our co-graft model. However, none of the current 
fibroblasts expressing Cre mouse lines are truly fibroblasts specific. For example, the Cre from 
Fsp1-cre mouse also expresses in immune cells such as macrophages (110). The depletion of 
CCL2 from macrophages can potentially confound the results. Similarly, the Cre from aSMA-
Cre mouse expresses in endothelial cells besides CAFs (111), and endothelial cells are also 
implicated in CCL2 function. To overcome those, a more complicated mouse model may be 
needed, such as by creation of bone marrow chimeric mouse in Fsp1-Cre;CCL2flox with wildtype 
bone marrow. This will eliminate the confounding effect of CCL2 function on macrophages.  
 Secondly, we have used the immune-comprised nude mice as tumor host, to facilitate the 
study of human breast cancer cells. However, CCL2 has been indicated in tumor immunity 
regulation through MDSC recruitment (41). Thus, an immunocompetent mouse model is needed 
to address the potential dual function of CCL2 in immune cells recruitment and direct cancer cell 
signaling. Toward this, we have initiated a pilot project in developing a syngeneic mouse model 
by grafting mammary tumor cell line 4T1 into its cognate Balb/c mouse (112). Preliminary data 
indicated that the 4T1 tumor grew rapidly and spontaneously metastasized to the lung. Given that 
CCR2 is also highly expressed in 4T1 cell line (39), this mouse model will provide a valuable 
tool to study the effect of CCL2 in breast cancer in immunocompetent condition. This model will 
also provide opportunities to address the CCL2/CCR2 signaling in breast cancer metastasis. 
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 To translate our studies into a potential clinical application, additional pre-clinical studies 
are needed. It will be critical to utilize additional CCL2/CCR2 signaling targeting reagents, such 
as CCR2 inhibitor, to test their efficacy in a preclinical mouse model. A few pharmaceutic 
companies have CCR2 inhibitors in clinical trials (113). A potential collaboration with them will 
enable us access to those drug candidates. In the potential pre-clinical studies, we will first test 
the efficacy of those CCR2 inhibitors in a panel of breast cancer cell lines, with especially 
focusing on basal-like cell lines. It will also be interesting to compare the sensitivity of basal-like 
breast cancer cells vs. cell lines from other subtypes in response to CCR2 inhibition. Lastly, 
CCR2 inhibition will be studied in vivo using mouse model of basal-like breast cancer. Success 
of these studies will provide confirmative supports in pursuing CCL2/CCR2 as therapeutic 
targets in basal-like breast cancer.    
 In addition, most of our studies have focused on targeting CCL2/CCR2 signaling alone. 
To achieve a durable clinical response, a potential strategy is developing a combinational therapy 
with CCL2/CCR2 inhibition. Our studies indicate that the CCL2 signaling potentially interacts 
with RAS signaling pathways in promoting cancer progression. Thus, it will be rational to test 
the efficacy to inhibition CCL2 signaling and RAS pathways in combination. In addition, CCL2 
has been reported to promote cell survival in breast cancer cells in response to chemotherapy 
(39). CCL2 expression in vivo has also promoted cancer recurrence in response to radiation 
therapy (114). Currently, clinical trials have been focusing on combining CCR2 inhibition with 
combination of immunotherapy. Thus, it will be critical to determine the best combination 
strategy in targeting CCL2 signaling.       
 In this study, our focus is mostly on how fibroblasts promote breast cancer progression. It 
is also interesting to determine the influence of cancer cells on stromal fibroblasts. Cancer 
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associated fibroblasts stay in an activated status (15). Those indicate that there is a continuous 
activation signal, most likely, coming from cancer cells, to maintain fibroblast activation status 
(115,116). We have observed the chemokine CCL2 expression is generally higher in CAFs 
compared to NAFs, indicating an activation related feature. CAFs are also known expressing 
high level of other chemokines, such as CXCL12 (117). It will be interesting to determine 
whether there are common upstream signaling pathways that are induced by cancer cells, and 
promote chemokine production. Common inflammatory signaling pathways, such as NF-ĸβ, can 
serve as potential candidates (115,118). Those interactions can be studied by analyzing CCL2 
expression regulation in fibroblasts, in context of responding to cancer cell stimulation. 
Inhibition of a common upstream pathway in CAFs can be a potential strategy to overcome 
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